Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
01/2012 | Recent  |  14:  |  |  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions January recently filed with US Patent Office 01/12

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
01/26/2012 > 204 patent applications in 153 patent subcategories. recently filed with US Patent Office

20120021968 - Methods for treating or preventing urological inflammation: P

20120021969 - Prosthetic implant shell: Methods for improving ejaculate of a patient in need thereof are presented, more particularly, methods for increasing ejaculate volume/prostatic fluid to increase viability of sperm contained therein by administration of a neurotoxin to the prostate of the patient, are provided.... Agent: Allergan, Inc.

20120021967 - Synthetic antibodies: The present invention provides methods for synthetic antibodies, methods for making synthetic antibodies, methods for identifying ligands, and related methods and reagents.... Agent: Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And Behalf Of Arizona

20120021970 - Methods for preventing or treating mitochondrial permeability transition: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of... Agent:

20120021971 - Functional food product comprising heat shock protein or a hydrolysate thereof: The invention relates to a heat shock protein from alfalfa and/or a hydrolysate of a heat shock protein from alfalfa in the manufacture of a food product for the prophylactic or therapeutic treatment of a chronic inflammatory disorder. Further, the invention relates to a clinical food product comprising heat shock... Agent: Alfa Biogene International B.v.

20120021974 - Novel inhibitor of angiogenesis: The invention relates to a method of treatment for states related to inhibition of angiogenesis and endothelial cell proliferation comprising administering an effective amount of vimentin or its derivatives or its fragments, to a subject in need thereof. Further, the invention relates to a pharmaceutical composition and a medicament comprising... Agent: Ibcc Holding As

20120021973 - Peptides for treatment of obesity: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the... Agent: Novo Nordisk A/s

20120021972 - Peptidomimetics with glucagon antagonistic and glp 1 agonistic activities: The present invention provides novel peptidomimetics, of formula (I), which primarily act as glucose dependent insulin secretagogues. Furthermore, it was found that these peptidomimetics showed glucagon receptor antagonistic activity, along with the GLP-I receptor agonistic activity.... Agent:

20120021975 - Antibiotic peptides: The invention relates to a peptide or peptide derivative having the general formula: Sub1-X1-D2K3-P4-P5-Y6-L7-P8-R9-P10-X2-P12-P13-R14-X3-I16-P17/Y17-N18-N19-X4-Sub2, wherein X1 is a non-polar, hydrophobic group or a positively charged group, D2 is asparagine or glutamine, K3, X2, and X4 are positively charged groups, X3 is a positively charged group, proline, or a proline derivative;... Agent: Amp-therapeutics Gmbh & Co., Kg

20120021976 - Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders: The present invention relates to Bicyclic Piperidine and piperazine Derivatives, compositions comprising a Bicyclic Piperidine and piperazine Derivative, and methods of using the Bicyclic Piperidine and piperazine Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a GPCR... Agent:

20120021977 - Promotion of healthy catch-up growth: The use of a protein source comprising bovine casein proteins for the preparation of a nutrional composition for administration to an infant, young child or adult during or after a period of catch-up growth or weight recovery, following a period of growth restriction or weight lost, so as improve growth... Agent: Nestec S.a.

20120021978 - Combination of an insulin and a glp-1-agonist: The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist.... Agent: Sanofi-aventis Deutschland Gmbh

20120021979 - Glp-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction: The present invention involves the use of GLP-1 and its analogs or GLP-1 receptor agonists to modulate dopamine transporter signaling. The implications of this ability include the use of MT-1 and its analogs or GLP-1 receptor agonists, such as exendin-4, to blunt behavioral response to addictive drugs, to decrease drug... Agent: Vanderbilt University

20120021980 - Compositions for drug administration: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various... Agent: Aegis Therapeutics, Inc.

20120021981 - Compositions to prevent and treat type-1 diabetes: The present invention is based on the discovery that Humanin and humanin analogues protect pancreatic beta cells in vitro and in vivo from apoptosis. Accordingly, humanin and its analogues are useful for preventing and treating diabetes and promoting beta cell survival in a number of applications.... Agent: The Regents Of The University Of California

20120021982 - Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction: The present invention features pharmaceutical compositions and methods of using the pharmaceutical compositions for treating left ventricular diastolic dysfunction. In particular, the pharmaceutical compositions include an apolipoprotein complex comprising a lipid fraction and a protein fraction.... Agent:

20120021983 - Compositions and methods for diagnosis and prognosis of cancer and progression, and for screening anti-cancer agents: MicroRNA (miRNA) profiling of cells showed unique miRNA signatures for each of three Akt isoforms. Among differentially regulated miRNA species, the miR-200 family was downregulated in Akt2-expressing cells. Akt1 knockdown inhibited expression of miR-200 and promoted TGFβ-induced epithelial-mesenchymal-transition (EMT) and a stem cell like phenotype. Carcinomas developing in MMTV-cErb2/Akt1−/− mice... Agent: Tufts Medical Center, Inc.

20120021985 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Human Genome Sciences, Inc.

20120021984 - Glycoprotein hormone analogs: This invention relates to the field of glycoprotein hormone analogs and their uses as agonists, antagonists, targeting vectors, and immunogens. In particular, this invention describes a method for stabilizing a heterodimer that permits the preparation of functional glycoprotein hormone analogs. The analogs of present invention comprise at least one alpha... Agent: University Of Medicine And Dentistry Of New Jersey

20120021986 - Protecting and repairing cartilage and musculoskeletal soft tissues: Provided herein are compositions and methods related to promoting protection or repair of articular cartilage and/or musculoskeletal soft tissue by contacting the cartilage, tissues or cellular components thereof with a parathyroid hormone/parathyroid hormone-related protein (PTH/PTHrP) receptor agonist or releasing factor.... Agent: University Of Rochester

20120021987 - Mucin 3 egf-like domains: The invention provides for a mucin3 polypeptide, a polypeptide including a mucin3 EGFlike domain, and nucleic acids encoding such polypeptides. The invention also provides for methods of treating an individual that has or is at risk of developing a disease or condition of the alimentary canal using such polypeptides or... Agent: Mucimed, Inc.

20120021988 - Methods for treating immune thrombocytopenia: Polypeptides and other compounds that can bind specifically to the CH2-CH3 cleft of an immunoglobulin molecule, and methods for using such polypeptides and compounds to inhibit Fc-mediated immune complex formation in autoimmune/immune thrombocytopenia.... Agent:

20120021989 - Genetic markers for risk management of atrial fibrillation and stroke: The invention relates to procedures and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with risk of these conditions. The invention further relates to kits encompassing reagents for... Agent: Decode Genetics Ehf.

20120021990 - Peptides useful as dual caspase-2/-6 inhibitors and their biological applications: The present disclosure relates to peptides having a core sequence as described herein as well as application of the disclosed technology as inhibitors of caspase-2 and/or -6 activity.... Agent:

20120021991 - Use of a botulinum neurotoxin to alleviate various disorders: Methods for treating obsessions and compulsions by local administration of a Clostridial toxin. The obsessions or compulsions can be eye poking, body rocking, finger biting, counting, checking and related disorders treated by low dose, intramuscular administration of a botulinum toxin.... Agent: Allergan, Inc.

20120021992 - Methods for improving neurological outcome after neural injury and neurodegenerative disease: Thymosin β4 can be used to treat neuronal and brain injuries that are accompanied by neuronal cell death or injury, including injuries caused by stroke or trauma and injuries caused by neurological and neurodegenerative disease. In particular, stroke and multiple sclerosis are examples of conditions which may be ameliorated by... Agent: Henry Ford Health System

20120021994 - Novel cancer antigen eef2: The present invention provides a method for detecting cancer using a protein expressed in various cancers, and a pharmaceutical composition for the treatment or prevention of such cancer using the protein as an indicator. Furthermore, the present invention provides a pharmaceutical composition containing a cancer antigen peptide derived from the... Agent:

20120021995 - Polypeptides that bind trail-r1 and trail-r2: Agonists for TRAIL death receptors including polypeptides that bind to TRAIL death receptor TRAIL-R1 (DR4) and/or TRAIL-R2 (DR5) and optionally having a multimerizing, e.g. trimerizing domain. Agonists are described that do not bind to TRAIL decoy receptors. The multimerizing domain may be derived from human tetranectin. The agonists can induce... Agent: Anaphore, Inc.

20120021993 - Protein scaffold library based on kringle domain structure and uses thereof: There are provided a Kringle domain structure, comprising: inducing artificial mutations at amino acid residues except for conserved amino acid residues that are important to maintain the structural scaffold of a Kringle domain; and protein scaffold variants, based on the Kringle domain structure, which modulate the biological activities of a... Agent: Ajou University Industry-academic Cooperation Foundation

20120021996 - Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an α-2-macroglobulin (α2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an α2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment... Agent: University Of Connecticut Health Center

20120021997 - Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an α-2-macroglobulin (α2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an α2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment... Agent: University Of Connecticut Health Center

20120021998 - Cancer diagnosis and treatment methods of use: The present invention relates to a method for treating a subject suffering from growth of AR-containing tumor cells, comprising administrating the subject an effective amount of DDB2. The present invention also relates to a kit for the diagnosis of cancer.... Agent: National Taiwan University

20120021999 - Pro-apoptotic peptides: The invention relates to chimeric peptides useful as pro-apoptotic agents, for inhibition of in vitro cell proliferation and for treatment of tumors.... Agent:

20120022000 - Use of a peptide in the treatment or prevention of metastasis: The present invention relates to a peptide useful for the preparation of a medicament for the treatment or prevention of metastasis. Furthermore, it relates to a method of treatment or prevention of metastasis comprising administering to a subject in need thereof, a therapeutically effective amount of the peptide of the... Agent: Universite De Lausanne

20120022001 - Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle: A method of parenterally administering a composition, the method including parenterally administering to a person a composition including at least one omega-3 fatty acid and at least one drug, wherein the at least one omega-3 fatty acid source and the at least one drug are administered simultaneously.... Agent: Stable Solutions LLC

20120022003 - Method of using diketopiperazines and composition containing them: m

20120022002 - Sustained release sirna for ocular drug delivery: The present invention provides an ocular implant comprising siRNA complexed with a transfection agent selected from the group consisting of cationic lipids and short cell penetration peptides, wherein said complex is associated with a biocompatible polymer. Said biocompatible polymer comprises a polymeric matrix configured to release said complex into the... Agent:

20120022004 - Treatment of t-cell mediated diseases: The invention provides a method of treating T-cell mediated diseases and a method of inhibiting the activation of T-cells using certain diketopiperazines. The invention also provides methods of synthesizing diketopiperazines and pharmaceutical compositions comprising certain diketopiperazines. The invention further provides methods of making improved pharmaceutical compositions of proteins and peptides... Agent:

20120022005 - Synthetic dragline spider silk-like proteins: The present application relates to isolated amino acid sequence comprising multiple repeats of a semi-synthetic spider silk protein domain, or any functional homolog, variant, derivative, fragment or mutant thereof. The amino acid sequence of the invention further comprises an N-terminal region and a C-terminal region. The invention further provides a... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.

20120022006 - B-lymphocyte stimulator binding polypeptides and methods based thereon: Binding polypeptides that specifically bind B lymphocyte stimulator protein or B lymphocyte stimulator-like polypeptides can be used in methods of the invention for detecting, diagnosing, or prognosing a disease or disorder associated with aberrant B lymphocyte stimulator or B lymphocyte stimulator receptor expression or inappropriate function of B lymphocyte stimulator... Agent: Human Genome Sciences, Inc.

20120022007 - Method and composition for modulating canonical wnt pathway using folate and inositol: The canonical Wnt signaling pathway is implicated in many disorders including neural tube defects, limb malformations, and heart defects, developmental disorders associated with alcohol exposure (fetal alcohol syndrome) or exposure to bipolar medications (i.e. lithium), wound healing, and Alzheimer's disease. Elevated plasma homocysteine (HCy), which results from folate (folic acid,... Agent: University Of South Florida

20120022008 - Compounds and method for inhibiting the activity of gelatinase and collagenase: Compounds extracted from Rhodiola rosea have ability to inhibit gelatinases and collagenases activity. The compounds have the chemical structure as shown below.... Agent: Taipei Medical University (tmu)

20120022009 - Tannate dry powder formulations: Dry powder tannate compositions containing bioactive agents, tannic acid, dispersants, and viscosity modifying agents are disclosed. Specifically, the bioactive agents are antihistamines, decongestants, antitussives, and anticholinergics. The dry powder formulations can further include pharmaceutically acceptable excipients. The dry powder formulations exhibit increased stability for extended shelf life. Bioactive agent tannate... Agent: Acella Pharmaceuticals, LLC

20120022010 - Use of flavonoids to increase the bioavailability of hesperetin: The present invention relates generally to the field of hesperetin bioavailability. One embodiment of the present invention is directed at a composition that allows to increase the bioavailability of hesperetin and consequently to maximize the beneficial health effects of hesperetin.... Agent: Nestec S.a.

20120022011 - Hsp90 inhibitors with modified toxicity: The invention provides purified 19-substituted geldanamycin derivatives, pharmaceutically acceptable salts thereof and prodrugs thereof that are potent Hsp90 binding agents that are useful for the treatment and/or the amelioration of symptoms of cancer and other proliferative tissue disorders.... Agent: The Regents Of The University Of Colorado

20120022012 - Glycosylated acetaminophen pro-drug analogs: The present invention relates to methods and compositions for the synthesis, production, and use of pro-drug analogs of the analgesic acetaminophen. This invention relates to a method for the production of a broad group of glycosides of acetaminophen derivatives.... Agent: Nutek Pharma Ltd.

20120022013 - Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms: The invention provides methods and compositions for modulating the life span of eukaryotic and prokaryotic cells and for protecting cells against certain stresses, e.g., heatshock. One method comprises modulating the flux of the NAD+ salvage pathway in the cell, e.g., by modulating the level or activity of one or more... Agent: President And Fellows Of Harvard College

20120022133 - Antisense modulation of cholesteryl ester transfer protein expression: Antisense compounds, compositions and methods are provided for modulating the expression of cholesteryl ester transfer protein. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding cholesteryl ester transfer protein. Methods of using these compounds for modulation of cholesteryl ester transfer protein expression and for treatment of... Agent: Isis Pharmaceuticals, Inc.

20120022144 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.... Agent: The University Of Western Australia

20120022145 - Antisense oligonucleotides for inducing exon skipping and methods of use thereof: An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.... Agent: The University Of Western Australia

20120022131 - Breast cancer related gene rqcd1: The present invention provides methods for detecting and diagnosing cancer, such methods involving the determination of the expression level of the RQCD1, GIGYF1 or GIGYF2 genes. These genes were discovered to discriminate cancer cells from normal cells. Furthermore, the present invention provides methods of screening for therapeutic agents useful in... Agent: Oncotherapy Science Inc.

20120022136 - Cellular genes regulated by hiv-1 infection and methods of use thereof: This invention provides cellular gene products which have anti-apoptotic activity in HIV-1 infected cells and provides agents for the inhibition of the cellular gene products.... Agent: The Children's Hospital Of Philadelphia

20120022141 - Compositions and methods for inhibiting expression of a gene from the jc virus: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the JC Virus (JC virus genome), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to... Agent:

20120022132 - Compositions and methods for inhibiting expression of mutant egfr gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a mutant Epidermal Growth Factor Receptor (EGFR), and methods of using the dsRNA to inhibit expression of mutant EGFR.... Agent:

20120022138 - Means for inhibiting the expression of ang2: The present invention is related to an siRNA comprising an antisense strand and a sense strand, wherein all or a portion of said antisense strand comprises an antisense duplex region, wherein all or a portion of said sense strand comprises a sense duplex region, wherein said antisense duplex region is... Agent: Silence Therapeutics Ag

20120022137 - Method of controlling initial drug release of sirna from sustained-release implants: The present invention provides an intraocular implant comprising siRNA combined with a excipient effective to retard the initial release of the siRNA from an implant, wherein said siRNA and excipient is associated with a biocompatible polymer (e.g., a polymeric matrix), configured to release said siRNA into the eye of a... Agent:

20120022130 - Method of regulating nfatc2 activity in lymphocytes: A method of decreasing NFATc2 activity in a lymphocyte includes administering to the lymphocyte an amount of an NFATc2 mRNA antagonist that binds to a binding site on the 3′UTR of NFATc2 mRNA effective to decrease the activity of NFATc2 mRNA in the lymphocyte.... Agent:

20120022140 - Method of treating a cancer with a survivin antisense oligonucleotide and paclitaxel: Provided is a method of treating cancer of the stomach, comprising administering to a patient a therapeutically effective combination of a Survivin antisense oligonucleotide and paclitaxel.... Agent: Eli Lilly And Company

20120022134 - Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mrna: The invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing said cell with a molecule that binds to a continuous stretch of at least 21 nucleotides within... Agent: Prosensa B.v.

20120022135 - Phd2 inhibition for blood vessel normalization, and uses thereof: A key function of blood vessels, to supply oxygen, is impaired in tumors because of abnormalities in their endothelial lining. PHD proteins serve as oxygen sensors and may regulate oxygen delivery. Therefore the role of endothelial PHD2 in vessel shaping by implanting tumors in PHD2+/− mice was studied. Haplodeficiency of... Agent: Vib Vzw

20120022128 - Pkib and naaladl2 for target genes of prostate cancer therapy and diagnosis: The invention features methods for detecting prostate cancer, especially hormone-refractory prostate cancer (HRPC) or castration-resistant prostate cancer (CRPC), by detecting over-expression of PKIB or NAALADL2 compared the normal organs. Also disclosed are methods of identifying compounds for treating and preventing prostate cancer including HRPC, based on the over-expression of PKIB... Agent: Oncotherapy Science, Inc.

20120022142 - Rna interference mediated inhibition of signal transducer and activator of transcription 1 (stat1) gene expression using short interfering nucleic acid (sina): The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of STAT1 gene expression and/or activity, and/or modulate a STAT1 gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic... Agent: Merck Sharp & Dohme Corp.

20120022143 - Rna interference mediated inhibition of the thymic stromal lymphopoietin (tslp) gene expression using short interfering nucliec acid (sina): The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of TSLP gene expression and/or activity, and/or modulate a TSLP gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic... Agent: Merck Sharp & Dohme Corp

20120022139 - Short interfering ribonucleic acid (sirna) for oral administration: Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification.... Agent: Novartis Ag

20120022129 - Targeting of histone deacetylase 2, protein kinase ck2, and nuclear factor nrf2 for treatment of inflammatory diseases: Methods for the treatment or prevention of diseases which are caused by the degradation of histone deacetylase 2 (HDAC2) in cells are described. The diseases which may be treated by the methods of the invention include chronic obstructive pulmonary disease (COPD) and asthma. The invention provides methods for treating or... Agent:

20120022146 - Signal activated molecular delivery: Provided herein are signal activatable molecular constructs for enzyme-assisted delivery of molecules and related components, such as a sensor domain, compositions, methods and systems.... Agent:

20120022014 - Tetrahydropyran nucleic acid analogs: The present disclosure describes tetrahydropyran nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, novel tetrahydropyran nucleoside analogs are provided having at least one chiral substituent that are expected to be useful for enhancing one or more properties of oligomeric compounds such as nuclease... Agent:

20120022015 - Method of treatment and supplement: A method of treatment and associated nutritional combination is disclosed. The method of treatment includes providing a patient with a nutritional combination including appropriate amounts of riboflavin, pyridoxine hydrochloride, and cyanocobalamin. The combination may further include thiamine mononitrate and calcium pantothenate, and may be in the form of an oral... Agent:

20120022016 - Compounds and methods for selectively targeting tumor-associated mucins: The present invention relates to pharmaceutical compositions containing tumor-selective targeted inhibitor glycoconjugates. These bioconjugates are ALK5 inhibitors covalently bound to biocompatible carrier molecules which selectively target and specifically bind to Muc4 that is overexpressed on a variety of tumor cell types. The ALK5 inhibitors are conjugated to tumor targetable glycans... Agent:

20120022018 - Anti-viral properties of aloe vera and acquired immune deficiency syndrome (aids) treatment: A pharmaceutical composition comprising a combination of formulations derived from Aloe vera for the treatment of Acquired Immune Deficiency Syndrome (AIDS) or HIV infection is described herein. The composition comprises: (i) an injectable sterile polymannan extract, (ii) Raidox (aloe anthraquinones and their diacetyl derivatives), and (iii) a freeze dried aloe... Agent: North Texas Medical Associates

20120022017 - Composition and a method thereof: The present invention describes a palatable and orally administrable form of composition comprising proteins, galactomannans and base matrix optionally along with acceptable additives.... Agent: Avesthagen Limited

20120022019 - Medicinal steroids cream and a process to make it: The present invention relates to a composition for treating skin inflammation, along with skin rejuvenation. More particularly, the present invention relates to a pharmaceutical cream comprising a biopolymer, and a corticosteroid. It discloses a composition for treating skin inflammation, along with skin rejuvenation containing a) a biopolymer in the form... Agent: Apex Laboratories Private Limited

20120022020 - Pharmaceutical forms for the release of active compounds: A pharmaceutical composition containing a sulfated glycosaminoglycan drug and a polycationic polymer or copolymer wherein the proportion of ammonium groups in the pharmaceutical composition is between 0.01-2.0 μmol ammonium groups/mg pharmaceutical composition, the proportion of glycosaminoglycan in the pharmaceutical form is between 15% to 50% w/w, and the pharmaceutical composition... Agent: Laboratorios Farmaceuticos Rovi S.a.

20120022021 - Mixtures of strobilurins with 1-methylcyclopropene: p

20120022022 - Novel inhibitors of chymase:

20120022023 - Hydraulic cements, methods and products: Non-aqueous hydraulic cement compositions comprise a non-aqueous mixture of a powder composition and a non-aqueous water-miscible liquid. In one embodiment, powder composition is a Brushite or Monetite-forming calcium phosphate powder composition. In another embodiment, the powder composition comprises porous β-tricalcium phosphate (β-TCP) granules and at least one additional calcium phosphate... Agent:

20120022024 - Anti-bacterial compositions and methods including targeting virulence factors of staphylococcus aureus: This disclosure relates to compositions and methods including for the inhibition, prevention, and/or treatment of microbial infections, including infections from such pathogens as Staphylococcus aureus.... Agent: The Board Of Trustees Of The University Of Illinois

20120022025 - Crystalline form c of tigecycline dihydrochloride and methods for its preparation: The present invention relates to crystalline form C of Tigecycline dihydrochloride and to methods for the preparation of the same. Furthermore the present invention relates to the use of crystalline form C of Tigecycline dihydrochloride as an intermediate for the preparation of an anti-infective medicament. Moreover the present invention relates... Agent: Sandoz Ag

20120022026 - Method of treating cancer: The present invention relates to a method of treating or preventing hyperproliferative disease in a body tissue of a subject, comprising the steps of administering to a subject in need thereof a therapeutically effective amount of an agent that induces double strand breaks in the DNA of the hyperproliferative cells... Agent: Academisch Medisch Centru Bij De Universiteit Van Amsterdam

20120022027 - Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel semicarbazides, sulfonyl carbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis... Agent: Siga Technologies Inc.

20120022028 - Sgc stimulators or sgc activators in combination with pde5 inhibitors for the treatment of erectile dysfunction: The present invention relates to soluble guanylate cyclase (sGC) and to phosphodiesterases (PDEs) and the pharmacology of sGC stimulators, sGC activators and PDE inhibitors. More particularly, the invention relates to the use of sGC stimulators and sGC activators in combination with PDE5 inhibitors for preparation of medicaments for the treatment... Agent: Bayer Pharma Aktiengesellschaft

20120022029 - Topical pain reliever and method of making the same: A topical pain reliever and method of making the same is disclosed. The topical pain reliever may comprise effective amounts of water, glycerine, analgesic agent such as salicylic acid or a derivative thereof, and alcohol. The method of making the topical pain reliever may maintain the analgesic agent in suspension... Agent:

20120022031 - Composition and methods of treatment of bacterial meningitis: A diluted solution of ceftiofur sodium is intrathecally or ventricularly delivered to effectively treat bacterial meningitis while maintaining the patient's threshold and reducing the likelihood of seizure.... Agent: Nbr Pathfinder LLC

20120022030 - Tetracyclic lactame derivatives: d

20120022032 - Corticosteroid compositions and methods of treatments thereof: This invention relates to steroidal solutions for the preparation of medicaments and drug products useful for treating diseases of the upper and lower airway passages. Various embodiments of the present invention provide compositions, compositions and dosage forms with mometasone furoate in a dissolved state that are suitable for inhalation and... Agent: Schering Corporation

20120022033 - Methods for decreasing cardiovascular risk in postmenopausal women: Methods for decreasing the risk of cardiovascular events in postmenopausal women having a high risk for a cardiovascular event are provided. In particular, methods for decreasing the risk of cardiovascular events in postmenopausal woman at high risk for cardiovascular events by administering to the woman a therapeutically effective amount of... Agent: Biosante Pharmaceuticals, Inc.

20120022034 - Methods for reducing or neovascularization or edema: Methods for reducing or preventing neovascularization or edema in the eye by implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.... Agent: Allergan, Inc.

20120022035 - Polymorphic and amorphous salt forms of squalamine dilactate: The invention relates to select squalamine salts, methods of their synthesis, their therapeutic use and their advantages relating to manufacturing, product stability and toxicity. More specifically, this application is directed to various forms of the dilactate salt of squalamine and their utility in inhibiting neovascularization and endothelial cell proliferation.... Agent:

20120022036 - Method of treating osteoporosis: A method for treating osteoporosis and related methods are disclosed. The methods generally comprise administering to a patient in need of treatment an effective amount of tris(8-quinolinolato)gallium(III) or an analog thereof.... Agent: Niiki Pharma Inc.

20120022037 - Aqueous hair cleansing agent: The present invention relates to an aqueous hair cleansing agent which includes the following components (A), (B): (A) sulfate-type anionic surfactant having a specific structure, (B) polyoxyethylene alkyl ether-type nonionic surfactant having a specific structure, and water, wherein ratio of weight represented by (B)/((A)+(B)) is 1% to 25%.... Agent: Kao Corporation

20120022038 - Animal treatment formulation and methods of use: The present invention relates to a formulation for administration to the teat canal of the mammary gland of an animal, the formulation including: a physical barrier material, characterised in that the formulation includes sufficient antibiotic in relation to physical barrier material such that the formulation is configured to disintegrate over... Agent: Mastitis Research Centre Limited

20120022039 - Novel substituted indanes, method for the production thereof, and use thereof as drugs: The invention relates to substituted indanes and derivatives thereof, to physiologically acceptable salts and physiologically functional derivatives thereof, to the production thereof, to drugs containing at least one substituted indane according to the invention or derivative thereof, and to the use of the substituted indanes according to the invention and... Agent: Sanofi

20120022040 - Antimicrobials: Compounds useful as antimicrobials are provided, as are methods of use and preparation of such compounds and compositions containing such compounds. In one embodiment, the compounds are derivatives having a carbapenem core, and are useful for treating a microorganism infection.... Agent:

20120022042 - Carbocyclic glyt1 receptor antagonists: m

20120022041 - Substituted heterocyclic compounds: Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as vascular disease and autoimmune diseases.... Agent: Bristol-myers Squibb Company

20120022043 - Pyrazolopyrimidine jak inhibitor compounds and methods: The invention provides JAK kinase inhibitors of Formula Ia, enantiomers, diasteriomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R7 and Z are defined herein, a pharmaceutical composition that includes a compound of Formula Ia and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the... Agent: Genentech, Inc.

20120022044 - Triazole derivatives for treatment of alzheimer's disease: According to the invention there is provided a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof; wherein the variables are as defined herein. The compounds selectively attenuate the production of Aβ42 and hence are useful in treatment of Alzheimer's disease and related conditions.... Agent:

20120022045 - Bridged compounds as hiv integrase inhibitors: Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: the asterisk * in Q denotes the point of attachment to the rest of the compound; and n, L1, L2, X1, X2, χ3, Y, Z, R1, R2 and R3 are defined herein. The N compounds are... Agent:

20120022046 - Thienopyridine derivatives for the treatment and prevention of dengue virus infections: Methods and pharmaceutical compositions for treating viral infections, by administering certain thienopyridine derivative compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by flavivirus is disclosed, i.e., including... Agent:

20120022047 - Process for the purification of eslicarbazepine acetate: The present invention relates to the purification and particle size of eslicarbazepine acetate. The present invention also relates to the physical characteristics of solid state eslicarbazepine acetate, and pharmaceutical compositions containing the same.... Agent: Glenmark Generics Ltd

20120022048 - Anti-proliferative substituted pyrazolo[3,4-d]pyrimidines derivatives (spp) to inhibit immune activation, virus replication and tumor growth: A family of pyrazolo[3,4-d]pyrimidine derivatives (SPPs) with different substituents on the pyrimidine and pyrazolo rings have been characterized with a panel of tests demonstrating their effects in cell proliferation, toxicity, apoptosis and inhibition of virus replication. We have identified compounds and molecular structures suitable for the treatment of viral infection... Agent:

20120022049 - Nicotinic receptor agonists for the treatment of inflammatory diseases: Nicotine receptor agonists or analogs or derivatives thereof for treating inflammatory pulmonary diseases, and pharmaceutical compositions including nicotine receptor agonists or analogs or derivatives thereof. Compounds of formula wherein R1, R2, Xa and Ya are as defined herein are also provided.... Agent: Universite Laval

20120022050 - Histamine h3 inverse agonists and antagonists and methods of use thereof: Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release... Agent:

20120022051 - Rapid onset liquid midazolam composition for buccal administration: This application discloses liquid compositions for administration to a patient comprising midazolam and a pharmaceutically acceptable carrier, wherein the pH of the composition is about 6 or higher, the composition comprises less than about 200 mg/ml cyclodextrin, and at least about 50% of the midazolam is present in solution. Uses... Agent: Special Products Limited

20120022052 - Small molecule inhibitors of kynurenine-3-monooxygenase: The present invention relates to compounds of formula Ia or Ib below and their tautomers and/or pharmaceutically acceptable salts and compositions and methods of uses thereof.... Agent: The Will Of J. David Gladstone

20120022054 - Novel substituted aryl derivatives, their process of preparation and their therapeutical uses as anti-hiv agents: The present invention concerns novel substituted aryl derivatives, their process of preparation and their use for inhibiting virus replication and for treating viral diseases or disorders such as HIV and/or HCV infection.... Agent: Laboratoire Biodim

20120022053 - Oxadiazine derivatives: e

20120022055 - Pest controlling composition: The present invention provides a pest controlling composition comprising, as active ingredients, an amide compound of the formula (I) and a neonicotinoid compound; and so on.... Agent:

20120022056 - Fused tricyclic derivatives for the treatment of psychotic disorders: Compounds of formula (I) wherein R1, R2, X, A, Y, B, Z1, Q, p, r and s are defined in the specification for treating inter alia psychotic disorders, depressive disorders, anxiety disorders and sexual dysfunctions.... Agent:

20120022058 - 4,5-dihydro-1h-pyrazole compounds and their pharmaceutical uses: Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.... Agent: Pfizer Inc.

20120022057 - Bicyclic compounds as inhibitors of diacyglycerol acyltransferase: The present invention relates to novel heterocyclic compounds as diacylglycerol acyltransferase (“DGAT”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired... Agent: Schering Corporation

20120022059 - Substituted furancarboxamides, and use thereof: The present invention relates to novel substituted furancarboxamides, methods for their production, their use for the treatment and/or prevention of diseases, as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially retroviral diseases, in humans and/or animals.... Agent: Aicuris Gmbh & Co. Kg

20120022061 - Benzo [c] phenanthridines as antimicrobial agents: The present invention provides compounds of formula I: formula (I) wherein X1-X4 and R1-R12 have any of the values defined in the specification, as well as salts and prodrugs thereof, which inhibit major molecular mechanisms associated with bacterial cell division and proliferation so as to be useful for the treatment... Agent:

20120022060 - Tricyclic azaindoles: Disclosed are dipyridyl-pyrrole derivative compounds and analogs thereof, pharmaceutical compositions comprising such compounds and processes for preparing the same. The compounds are useful in the treatment of diseases amenable to protein kinase signal transduction inhibition, regulation and/or modulation.... Agent: Merck Patent Gmbh

20120022062 - Flavanoid compounds and process for preparation thereof: The present invention relates to flavanoid compounds of general formula (X1) wherein: R1 is selected from a group consisting of morpholinyl, N-methyl piperizinyl, piperidinyl and N,N′-dimethylamino groups, and n ranges from 3 to 6, and process for preparation thereof. The present invention relates to the demonstration of anti Helicobacter pylori... Agent:

20120022065 - C-met modulators and method of use: The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways... Agent: Exelixis, Inc.

20120022064 - Dihydroquinolinone derivatives: e

20120022063 - Oligomer-cannabinoid conjugates: The invention relates to (among other things) oligomer-cannabinoid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated cannabinoid compounds.... Agent: Nektar Therapeutics

20120022066 - Insecticidal triazines and pyrimidines: The present invention describes novel triazines, their related pyrimidines and their use in controlling insects. This invention also includes new synthetic procedures, intermediates for preparing the compounds, pesticide compositions containing the compounds, and methods of controlling insects using the compounds.... Agent: Vestaron Corporation

20120022068 - Novel heterocyclic nf-kb inhibitors: e

20120022067 - Thiazole and oxazole-substituted arylamides as p2x3 and p2x2/3 antagonists:

20120022069 - Acrylamide compounds and the use thereof:

20120022070 - Heat shock protein 90 inhibitors, methods of preparing same, and methods for their use: Novel classes of molecular chaperone Heat shock protein 90 (Hsp90) inhibitors are disclosed. These compounds are useful in treating and preventing cancer and other Hsp90-related diseases and conditions, such as inflammation and neurodegenerative disorders. Methods of treating and preventing cancer and other Hsp90 related diseases and conditions are disclosed that... Agent: Emory University

20120022071 - Treatment of comorbid premature ejaculation and erectile dysfunction: The invention provides a method of treating comorbid premature ejaculation and erectile dysfunction. In particular, the method comprises administering an effective amount of a tramadol material and an effective amount of a phosphodiesterase inhibitor. The invention also provides a pharmaceutical composition comprising a pharmaceutically-acceptable carrier, a tramadol material and a... Agent:

20120022072 - Pterin analogs: Disclosed herein are analogs of tetrahydrobiopterin, compositions containing the same, and methods of treating an individual suffering from a condition responsive to tetrahydrobiopterin by administration of the analog. These analogs are contemplated for use wherever tetrahydrobiopterin is currently used to treat conditions responsive to tetrahydrobiopterin therapies.... Agent: Biomarin Pharmaceutical Inc.

20120022073 - Compound for the treatment of enteroviruses: The present invention relates to the treatment, alleviation, prevention or reduction in the incidence of symptoms, diseases or conditions resulting from or associated with enteroviruses, more particularly the enteroviral infections they cause.... Agent: Biota Scientific Management Pty Ltd

20120022074 - Organic compounds: The present invention relates to 1-aza-bicycloalkyl derivatives of Formula (I) wherein the substituents are as defined in the specification and to processes for their production to pharmaceutical compositions comprising them and to their use in the manufacture of a medicament for the treatment and/or delay of progression of psychotic and... Agent: Novartis Ag

20120022075 - Novel phenylpyrrole derivative: A represents, for example, an oxygen atom or sulfur atom, R1 represents, for example, a C1-C6 alkyl group, a C1-C6 alkoxy group or a C1-C6 halogenated alkyl group, A and R1 together with the carbon atom bonded thereto form a heterocyclic group that may be substituted with 1 to 3... Agent:

20120022076 - Derivatives of n-(arylamino)sulfonamides as inhibitors of mek: This invention concerns N-(2-arylamino)aryl sulfonamides, which are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases.... Agent:

20120022077 - Novel cyanopyrimidine derivative: The present invention relates to a novel cyanopyrimidine compound and a pharmaceutical composition which have a safe and potent adenosine A2a receptor agonistic activity.... Agent:

20120022078 - Aryl indole derivatives: A novel aryl indole derivative is provided that is effective as a preventive or remedy for various diseases. A compound represented by a formula (I) or a pharmaceutically acceptable salt thereof: (I) wherein R1 is a hydrogen atom, halogen, C1-6alkyl, haloC1-6alkyl, C1-6alkyloxy, or haloC1-6alkyloxy; R2 represents C1-6alkyl or haloC1-6alkyl; R3... Agent: Msd K.k.

20120022079 - Method for producing preparations of substances poorly soluble in water: n

20120022080 - Plasminogen activator inhibitor-1 inhibitor: The present invention provides a novel compound having plasminogen activator inhibitor-1 inhibitory activity, and an inhibitor of PAI-1 comprising the compound as an active ingredient. The present invention also provides a pharmaceutical composition having an inhibitory action on PAI-1 activity and being efficacious in the prevention and treatment of various... Agent: Renascience Co., Ltd.

20120022081 - Method of using diketopiperazines and composition containing them: e

20120022082 - Pyrazine derivatives:

20120022083 - Small molecule modulators of cell adhesion:

20120022084 - Substituted 5-fluoro-1h-pyrazolopyridines and their use: The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular... Agent: Bayer Schering Pharma Aktiengesellschaft

20120022085 - Process for obtaining extracts containing methylxanthine derivatives from cakes of plants of the genus theobroma, as well as composition and use of said extract: The present invention refers to a process for obtaining standardized extracts of methylxanthine derivatives from cakes of plants of the genus Theobroma such as cacoa and cupuaçu for use in a composition having potential anti-celullite lipolytic activity.... Agent:

20120022086 - Catecholamine derivatives for obesity and neurological disorders: Novel compounds, compositions, and methods related to the activation of the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing a catecholamine backbone and pharmaceutically acceptable salts, prodrugs, and derivatives thereof. Specifically, methods, compositions, and compounds for the... Agent: Emory University

20120022087 - Amorphous ambrisentan: The invention relates to amorphous ambrisentan, preferably together with a surface stabiliser in the form of a stable intermediate. The invention further relates to methods of producing stable amorphous ambrisentan and pharmaceutical formulations containing stable amorphous ambrisentan.... Agent: Ratiopharm Gmbh

20120022088 - Pharmaceutical combination of 5-fluorouracil and derivate of 1,4-dihydropyridine and its use in the treatment of cancer: e

20120022089 - Solid pharmaceutical dosage form: A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable... Agent: Abbott Laboratories

20120022091 - Key intermediates for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof: The present invention relates in general to the field of organic chemistry and in particular to the preparation of N-(4-(4-fluorophenyl)-6-isopropyl-5-methylpyrimidin-2-yl)-N-methylmethanesulfonamide (I), N-(4-(4-fluorophenyl)-5-(bromomethyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide (II) and N-(4-(4-fluorophenyl)-5-(hydroxymethyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide (III), key intermediates in preparation of Rosuvastatin.... Agent: Lek Pharmaceuticals D.d.

20120022090 - Novel substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators: wherein R1, R2, R3, R4, X, A1, A2, A3, A4, Y1, Y2, Y3 and Z have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said... Agent:

20120022092 - Protein kinase c inhibitors and uses thereof: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these... Agent:

20120022093 - Crystalline forms of oxymorphone hydrochloride: The present invention is directed to crystalline forms of oxymorphone hydrochloride.... Agent:

20120022094 - Pharmaceutical formulations: New and improved antihistaminic syrups are disclosed.... Agent: Schering Corporation

20120022095 - Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis: The present disclosure provides for a method and a topical composition to treat facial angiofibromas in Tuberous Sclerosis by applying from about 0.25% to about 2% rapamycin to a small body surface area.... Agent:

20120022096 - Pro-neurogenic compounds: This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such... Agent: Board Of Regents Of The University Of Texas System

20120022097 - Compositions and methods for treating cancer: The present invention is bis-acridine or bis-quinoline intercalators having a modified bis(4-aminophenyl)ether tether to improve activity, selectivity, solubility and bioavailability of the antitumor compound.... Agent: Trustees Of Dartmouth College

20120022098 - Compounds and methods for kinase modulation, and indications therefor: Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.... Agent: Plexxikon Inc.

20120022099 - Novel polymorphic forms of an azabicyclo-trifluoromethyl benzamide derivative: m

20120022100 - Organic compounds: and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting... Agent:

20120022101 - Salt and solvates of a tetrahydroisoquinoline derivative: (S)-2-(Diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in substantially pure form is described together with its sodium salt and solvates. Methods for preparing the compound, its sodium salt and its solvates and pharmaceutical compositions comprising them are also described.... Agent: Spinifex Pharmaceuticals Pty Ltd,

20120022102 - Method for preparation of pitavastatin and its pharmaceutical acceptable salts thereof: The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium.... Agent: Cadila Healthcare Limited

20120022103 - Antagonists of the trpv1 receptor and uses thereof: e

20120022104 - Pectin-containing jelly formulation: There is disclosed a technique for imparting an appropriate rupture strength and high drug-release properties to a jelly formulation comprising pectin. The jelly formulation of the present invention comprises a drug, pectin, and divalent metal ion, and further comprises a component selected from sucrose, maltitol and C3-C4 alditols, and a... Agent:

20120022105 - Grease-like gel for repelling rodents: Grease-like compositions are provided for repelling rodents. The compositions utilize nontoxic mineral, synthetic, or vegetable oil based gels containing silica, clay, urea, polytetrafluoroethylene, or metallic soap thickeners and capsaicin.... Agent: Pignx, Inc.

20120022106 - Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.... Agent: Celgene Corporation

20120022107 - 2-(piperidin-1-yl)-4-azolyl-thiazole-5-carboxylic acid derivatives against bacterial infections: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.... Agent: Astrazeneca Ab

20120022108 - Allosteric modulators of metabotropic glutamate receptors: The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R1 and R2 are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.... Agent: Addex Pharma Sa

20120022109 - Oxadiazole derivatives: The invention relates to oxadiazole compounds of formula I. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.... Agent: Merck Serono Sa

20120022110 - Pharmaceutical depot for 5-fluoro-2-[[(1s)-1-(5-fluoro-2-pyridyl)ethyl]amino]-6-[(5-isopropoxy-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile: A pharmaceutical depot comprising (i) 5-fluoro-2-[[(1S)-1-(5-fluoro-2-pyridyl)ethyl]amino]-6-[(5-isopropoxy-1H-pyrazol-3-yl)amino]pyridine-3-carbonitrile, or a pharmaceutically-acceptable salt thereof, as a pharmaceutical agent (PA) and (ii) a polymer which degrades to create an acidic microclimate, wherein the PA is released from the polymer upon polymer degradation.... Agent: Astrazeneca Ab

20120022111 - Spot-on pesticide composition: A spot-on pesticide composition for animals, specifically mammals, including dogs and cats, which composition comprises a combination of active components, including fipronil and a pyrethroid, and optionally an insect growth regulator, in doses and proportions which are parasiticidally effective against a variety of insects and pests, and in a formulation... Agent: Sergeant's Pet Care Products, Inc.

20120022112 - Use of anthranilamide derivatives for controlling insects and spider mites by drenching, soil mixing, furrow treatment, drip application, soil, stem or flower injection, in hydroponic systems, by planting hole treatment or dip application, floating or see: in which R1, R2, R3, R4, R5, A, X, Qx, Qy and n have the general meanings given in the description for controlling insects and/or spider mites by drenching, soil mixing, furrow treatment, droplet application, in hydroponic systems, by planting hole treatment, soil, stern or flower injection, dip application, floating... Agent: Bayer Cropscience Ag

20120022113 - Methods for suppressing tipdc trafficking or accumulation and preventing hypercytokinemia: The present invention features methods for preventing or ameliorating hypercytokinemia or preventing lethality-associated with infection by highly pathogenic strains of influenza virus by suppressing TNF-α/Inducible nitric oxide synthase-Producing dendritic cell trafficking or accumulation. In particular embodiments, the expression MyD88, CCR2, MCP-I or MCP-3 is targeted.... Agent:

20120022114 - Low-dose, non-irritating nicotine nasal composition to reduce the desire to smoke: A composition for administration to the nasal mucosa of a subject comprises a solution of nicotine or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable solvent. The composition has a nicotine concentration less than 0.08 mg/ml. The composition used alone assists in reduction of the desire of a subject... Agent: Laboratorio Pablo Cassara S.r.l.

20120022115 - Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases: Provided herein are hydroxypyridone derivatives, for example, a compound of Formula I, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.... Agent: Biotheryx Inc.

20120022116 - Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex: Disclosed are compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically related to GPR35, and/or GPR35-hERG signaling complex. For example, disclosed are compounds for preventing and/or treating diseases which are pathophysiologically related to GPR35 in a subject. The compounds having a formula (I), (II) or (III):... Agent:

20120022117 - Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol: A salt or cocrystal of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol (component a) and at least one acid component (b1) or at least one acid component (b2), wherein the salt or cocrystal of component (a) and component (b2) is present in crystalline and/or amorphous form, a pharmaceutical composition comprising said salt or cocrystal, and a... Agent: Gruenenthal Gmbh

20120022118 - Compounds for the treatment of proliferative disorders: s

20120022119 - Heterocyclic antagonists of prostaglandin d2 receptors: Described herein are heteroaryl compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the heteroaryl compounds described. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent... Agent: Amira Pharmaceuticals, Inc.

20120022120 - Antimycotic pharmaceutical composition: In a pharmaceutical composition for external use containing a compound such as luliconazole and/or a salt thereof, comprised are a higher alcohol which is in a liquid state at 1 atm and 25° C. and/or a diester of a dibasic acid, provided that a diester carbonate is excluded, and a... Agent: Pola Pharma Inc.

20120022121 - Indoles, derivatives and analogs thereof and uses therefor: Indole derivatives and analogous compounds and pharmaceutical compositions comprising the same are provided. Also provided are methods of using these compounds to inhibit tubulin polymerization in a cell associated with a proliferative disease or to treat cancer, metastatic cancer, resistant cancer or multidrug resistant cancer, including inter-alia: prostate cancer, breast... Agent:

20120022122 - Treatment and prevention of deleterious effects associated with alcohol consumption: The present invention provides to methods and compositions that treat or prevent deleterious effects associated with alcohol consumption including alcohol-induced flush reaction and hangover. The methods and compositions include famotidine and optionally succinic acid. The present invention further demonstrates compositions that include famotidine are effective at treating symptoms associated with... Agent:

20120022123 - Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof: The present invention relates to novel substituted (thiophenyl-carbonyl)imidazolidinones, methods for their production, their use for the treatment and/or prevention of diseases, as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially retroviral diseases, in humans and/or animals.... Agent: Aicuris Gmbh & Co. Kg

20120022124 - Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof: New polymorphs of Eltrombopag and Eltrombopag ethanolamine salt have been obtained and characterized. These polymorphs and pharmaceutical compositions comprising them are useful, for example, in treating conditions leading to thrombocytopenia.... Agent: Pliva Hrvatska D.o.o.

20120022126 - Method of treating diabetes mellitus: The invention provides methods of treating a diabetic subject comprising administering a glucosylceramide synthase inhibitor to the subject.... Agent: Genzyme Corporation

20120022125 - Pyrrolidine triple reuptake inhibitors: In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also... Agent:

20120022127 - Process for preparing pyrrolidinium salts:

20120022147 - 2, 6 xylidine derivatives for the treatment of pain: The disclosure herein provides a composition compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1. The compound of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof may be formulated as pharmaceutical composition to be used... Agent: Krisani Biosciences (p) Ltd

20120022148 - Curcuminoids in combination docetaxel for the treatment of cancer and tumour metastasis: The present invention relates to a curcuminoid for enhancing the clinical efficacy of Docetaxel for the treatment of cancers and metastases.... Agent:

20120022149 - Pharmaceutical composition with enhanced solubility characteristics: There are disclosed pharmaceutical compositions, particularly ophthalmic compositions, that contain relatively high concentrations of solubility enhancing polymer (e.g., polyether polymer, polyvinyl polymer or a combination thereof) for providing enhanced solubility of one or more therapeutic agents. In a preferred embodiment, the composition is a multi-dose topical aqueous ophthalmic composition that... Agent:

20120022150 - Treatment and prevention of benign pigmented moles (naevi) using artemisinine and the derivatives thereof: A method of treating a benign pigmented mole or a dermatomycosis. The method comprises locally applying to a subject in need thereof artemisinine and/or one or more structurally related compounds. Also disclosed is a plaster which comprises a topical formulation comprising artemisinine and/or one or more structurally related compounds.... Agent: Epipharm Gmbh

20120022152 - Anti-constipation composition: m

20120022151 - Method for preventing damage to nuclear membrane of skin cell by administering amentoflavone: Provided are a method for preventing damage to the nuclear membrane of skin cell including administering an effective amount of amentoflavone to a subject and a method for anti-aging including administering an effective amount of amentoflavone to a subject. By controlling the expression of defective lamin A induced by UV... Agent: Amorepacific Corporation

20120022153 - Tricyclic condensed heterocyclic compound, process of producing same, and use thereof: or an optical isomer thereof or a pharmaceutically acceptable salt thereof which can be isolated from the culture fluid of an actinomycete which belongs to the genus Streptomyces, wherein R1, R2, R5 and R6 each independently represent a hydrogen atom, a methyl group, a hydroxymethyl group, a hydroxyl group, or... Agent: Nippon Suisan Kaisha, Ltd.

20120022154 - N-hydroxy c29-amide derivatives of oleandrane: The present invention encompasses novel triterpene compounds of general formula I, wherein R3a, R3b, R11a, R11b, R31 and R32 are defined as in claim 1, which are suitable for the prevention and/or treatment of diseases mediated by 11 β-HSD and the use thereof for preparing a medicament having the above-mentioned... Agent: Onepharm Research & Development Gmbh

20120022156 - Delayed release, oral dosage compositions that contain amorphous cddo-me: Pharmaceutical formulations exhibit a desirably low Cmax, among other properties, that contain particles of amorphous bardoxolone methyl, either in pure form or in the form of a solid dispersion, admixed with particles of a hydrophilic binding agent. Such formulations possess the advantage of higher oral bioavailability, relative to formulations based... Agent: Reata Pharmaceuticals, Inc.

20120022155 - Use of aminaphtone for the preparation of a medicament for treating arteriopathies: The subject of the present invention is the use of aminaphtone for the preparation of a medicament for treating arteriophaties, in particular arteriophaties of a degenerative inflammatory type. Preferably, said medicament is formulated for oral administration... Agent: Fondazione Irccs "ca' Granda-ospedale Maggiore Policlinico"

20120022157 - Dosing and monitoring patients on nitrogen-scavenging drugs: The invention provides a method for determining a dose and dosing schedule, and making dose adjustments of patients taking PBA prodrugs as nitrogen scavengers to treat nitrogen retention states, including ammonia accumulation disorders as well as chronic renal failure, by measuring urinary excretion of phenylacetylglutamine and/or total urinary nitrogen. The... Agent: Ucyclyd Pharma, Inc

20120022158 - Solid-forming local anesthetic formulations for pain control: Solid-forming local anesthetic formulations for pain control can include a lidocaine base and tetracaine base, polyvinyl alcohol, water, and an emulsifier. The formulation can be prepared to be in a semi-solid state prior to application to a skin surface, can form a soft solidified layer after application, and can provide... Agent: Zars Pharma, Inc.

20120022159 - Amphiphilic star-like or scorpion-like macromolecules, various compositions and uses thereof: Biomedical uses of amphiphilic macromolecules include the use of such macromolecules in the form of nanoparticle formulations for the sequestration and/or removal of LDL, and for the treatment and prevention of atherosclerosis and atherosclerotic development. The invention also provides the use of amphiphilic macromolecule encapsulates for treating diseases including cancer... Agent:

20120022160 - Composition for external use on skin: It is intended to provide a cleansing cosmetic composition that quickly removes makeup from the skin, is easily applicable onto the skin without dripping from the hand or running on the face during application, and can freshen the skin because of being washed off thoroughly. The present invention provides a... Agent:

20120022161 - Acetycysteine compositions and methods of use thereof: A pharmaceutical composition and method for providing a reduction in side effects for human patients in need of therapy comprising the administration of a pharmaceutical composition comprising acetylcysteine is disclosed.... Agent: Cumberland Pharmaceuticals, Inc.

20120022162 - Mixed amino acid/mineral compounds having improved solubility: Mixed amino acid/mineral compounds can include at least two amino acids bound to a central mineral atom. The combination of amino acids can be tailored to provide improved solubility, absorption, and/or bioavailability of the mineral. Optionally, organic acids can be bound to the mineral or combined with the chelate in... Agent: Albion International Inc.

20120022163 - 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the therapy of prion diseases: Derivatives of 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid are useful for the prevention and/or treatment of prion diseases in animals and humans.... Agent: Chiesi Farmaceutici S.p.a.

20120022164 - External preparation comprising prostaglandin derivative: r

20120022165 - Transdermal compositions: The present invention is directed to transdermal compositions and the uses thereof. These compositions include at least one of the following components: a C1-C6 dialkyl, C12-C30 dialkyl quaternary ammonium salt, a C12-C30 fatty acid, a nitrogenous organic base, C12-30 fatty alcohol, monoglyceride or the reaction products thereof.... Agent: Microdermis Corporation

20120022166 - Methods for modulating macrophage proliferation using polyamine analogs: Methods for modulating macrophage proliferation in an individual afflicted with or at risk for a macrophage-associated disease are provided. The methods employ a polyamine analog, or salt or protected derivative thereof. Macrophage proliferation has been implicated in a number of serious disorders, including AIDS (HIV)-associated dementia, AIDS-associated non-Hodgkin's lymphoma, and... Agent:

20120022167 - Trans-clomiphene for metabolic syndrome: The present invention relates to the administration of compositions comprising an antiestrogen, preferably trans-clomiphene, for treating metabolic syndrome in a subject. The invention is also directed to methods for reducing fasting glucose levels in a subject by administering a composition comprising an antiestrogen, preferably trans-clomiphene.... Agent: Repros Therapeutics Inc.

20120022168 - Pest control agent, method for manufacture of pest control agent, and method for pest control: Disclosed are a pest control agent, a method for preparing a pest control agent, and a method for controlling a pest. Generally, the pest control agent is formed by providing a porous starch and an active control agent absorbed within the porous starch, and compressing the porous starch in the... Agent: Grain Processing Corporation

20120022169 - Hard capsule: s

20120022170 - Manufacture of tablet in a die utilizing powder blend containing water-containing material: The present invention features the present invention features a process for making a tablet by compacting a powder blend in a die platen to form a tablet shape, wherein the powder blend includes a pharmaceutically active agent and a water-containing material, and applying energy to the tablet shape for a... Agent:

  
01/19/2012 > 175 patent applications in 127 patent subcategories. recently filed with US Patent Office

20120015865 - Novel class of cationic lipids for transporting active agents into cells: A subject of the present invention is the development of a novel family of cationic lipids and their use as vectors for in vitro, ex vivo and in 5 vivo delivery of biologically active agents.... Agent: Oz Biosciences

20120015866 - Prodrugs of heteraromatic compounds: The present invention relates to prodrugs of parent drug compounds containing heteroaromatic NH groups.... Agent: Alkermes, Inc.

20120015867 - Therapeutic peptides and method: A polypeptide comprising one or more sequences derived from CDR2 or CDR3 of a TREM-1 protein, characterised by the ability to treat, ameliorate, or lessen the symptoms of conditions including sepsis, septic shock or sepsis-like conditions and IBD.... Agent: Novo Nordisk A/s

20120015868 - Metastin derivatives and use thereof: The present invention provides a metastin derivative in which the amino acids comprising metastin were modified by alternative chemical substituents resulting in metastin derivitives, having excellent blood stability and exhibiting cancer metastasis inhibiting action or cancer growth inhibiting action.... Agent: Takeda Pharmaceutical Company Limited

20120015869 - Antimicrobial aqueous solution and its preparation method: The antimicrobial aqueous solution of the present invention comprises an original undiluted aqueous solution containing: 25 μg/ml to 50 μg/ml of an amphipathic preservative comprising a monoglycerol monolaurate; and 12.5 μg/ml to 30 μg/ml of an ε-polylysine. In preparing the antimicrobial aqueous solution, dissolution of the amphipathic antimicrobial can be... Agent: Dentrochemical Co., Ltd.

20120015871 - Complement receptor 2 targeted complement modulators: Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are... Agent: Musc Foundation For Research Development

20120015872 - Complement receptor 2 targeted complement modulators: Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are... Agent: Musc Foundation For Research Development

20120015870 - Peptides and compositions for prevention of cell adhesion and methods of using same: Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of FDYDWY (SEQ ID NO: 2), SFSQNKSVHSFDYDWYNVSDQADLKN (SEQ ID NO: 3) or CSFSQNKSVHSFDYDWYNVSDQADLKNC (SEQ ID NO: 1), or any cyclized version thereof, and methods of using same, including for treatment of or... Agent: Tel Hashomer Medical Research, Infrastructure And Services Ltd.

20120015873 - Melanocortin analogs with antimicrobial activity: The present invention finds application in the therapeutic fields. In particular, it concerns new synthetic melanocortin peptides having improved antimicrobial activity.... Agent:

20120015874 - Novel inhibitors of retroviral reverse transcriptace: Disclosed are nucleic acid molecules, and methods of their use, which have a specific structure including a double helical domain and a G-quadruplex domain physically connected by a linker domain which may be nucleosidic or non-nucleosidic. These aptamers demonstrate potent inhibition of phylogenetically diverse primate lentiviral reverse transcriptases, which effect... Agent: The Curators Of The University Of Missouri

20120015875 - Use of oxandrolone in the treatment of burns and other wounds: The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically... Agent: Savient Pharmaceuticals, Inc.

20120015876 - Conjugates of glp-1 agonists and uses thereof: The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a GLP-1 agonist (e.g., exendin-4 or an exendin-4 analog). The compounds of... Agent: Angiochem Inc.

20120015877 - Use of gdf traps to increase red blood cell levels: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.... Agent: Acceleron Pharma Inc.

20120015878 - Use of adnf polypeptides for treating anxiety and depression: This invention relates to the use of ADNF polypeptides in the treatment of anxiety and/or depression. The present invention also relates to drug discovery assays using the ADNF polypeptide mechanism of action and target interaction, as well as the manufacture of medicaments, methods of application and formulation therefor. Embodiments of... Agent: Ramot At Tel Aviv University Ltd.

20120015879 - Unitary combinations of fsh and hcg: A novel ovulatory induction paradigm entails administration of hCG in combination with FSH during all stages of treatment, where the ratio of FSH to hCG is adjusted to optimize ovulatory stimulation and minimize complications. The use of compositions characterized by various FSH:hCG ratios enables the practitioner readily to tailor the... Agent: Ferring B.v.

20120015880 - Intranasal desmopressin administration: Disclosed is a family of intranasal spray dispensers for administering uniform low doses of desmopressin so as to achieve safe antidiuresis in human patients. The dispensers of the invention may be used in the treatment of nocturia, primary nocturnal enuresis, incontinence, urinary frequency, diabetes insipidus, or any disease or syndrome... Agent:

20120015881 - Kallikrein-inhibitor therapies: Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient.... Agent: Dyax Corp.

20120015882 - Composition for regulating autonomic nervous activity and method for regulating autonomic nerve: The present invention provides an orally ingestible composition and a method for regulating an autonomic nervous activity. In particular, the present invention provides an orally ingestible composition capable of suppressing an increase in a sympathetic nervous activity, and an orally ingestible composition capable of promoting a parasympathetic nervous activity. The... Agent:

20120015883 - Composition for regulating autonomic nervous activity and method for regulating autonomic nerve: The peptide/peptoid oligomers demonstrate the ability to inhibit fibrillization and oligomerization of Aβ and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals, including humans, associated with Aβ oligomerization. The present peptidomimetic oligomers are particularly valuable for the treatment... Agent:

20120015884 - Polypeptides for specific targeting to otx2 target cells: The invention relates to polypeptides which enable the specific targeting of a molecule of interest to homeoprotein Otx2 target cells. These polypeptides are defined by the general sequence: B1B2X1B3B4X2B5X3X4X5X6B6X7X8X9 (SEQ ID NO: 1), in which: B1, B2, B3, B4, B5 and B6are independently arginine or lysine; X1 and X8 are... Agent:

20120015885 - Compositions and methods for camkii inhibitors and uses thereof: Embodiments herein generally relate to methods, compositions and uses of CaMKII inhibitors. Other embodiments relate to methods, compositions and uses of agents that target CaMKII. Yet further embodiments relate to compositions, methods and uses of CaMKIIN-derived molecules and other CaMKII inhibitor molecules that inhibit autonomous CaMKII activity. In accordance with... Agent:

20120015886 - Method for preparing recombinant peptide from spider venom and method for relieving pain: The present invention relates to a method for producing a recombinant, spider toxin peptide and analgesic compositions containing said peptide. More specifically, the present invention relates to a method in which the gene for GsMTx4 is subcloned into a vector, so that it is linked to a secretion signal sequence... Agent: Seoul National University Industry Foundation

20120015887 - Synthetic peptide and uses thereof: A 4-copy branched peptide represented by a formula of (XA-XB-XC-XD-X1)4>(K-X2)2>K-X3. XA and XC separately represent an uncharged polar amino acid; XB and XD separately represent an alkaline amino acid; >K- represents lysine comprising two free activated amino groups for amino acid addition condensation reactions; X1 and X2 separately represents an... Agent: Yuansentai Biotech (tianjin) Inc.

20120015888 - T cell receptors and related materials and methods of use: The invention provides T cell receptors (TCRs) having antigenic specificity for a cancer antigen, e.g., tyrosinase. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a... Agent: The United States Of America, As Represented By The Secretary, Dept Of Health And Human Svcs

20120015889 - Method for the administration of ligands, agonists of ligands of the tnf family with reduced toxicity: The present invention concerns the use of a multimerized form of ligands of the TNF family for the preparation of a medicament for injection into an appropriate cavity of the body, for the treatment of diseases wherein cell proliferation has to be controlled wherein the ligand of the TNF family... Agent: Apoxis S. A.

20120015890 - Use of soluble forms of cd83 and nucleic acids encoding them for the treatment or prevention of diseases: The present invention provides for the use of soluble forms of CD83 and nucleic acids encoding them for the treatment of diseases caused by the dysfunction or undesired function of a cellular immune response involving dendritic cells, T cells and/or B cells. The invention moreover provides soluble CD83 molecules specifically... Agent: Argos Therapeutics, Inc.

20120015891 - Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof: The present invention provides long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer. In particular, the present invention provides a long acting pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate in depot form suitable for administering at a medically acceptable location in a subject in... Agent: Mapi Pharma Ltd.

20120015892 - Formulations of canfosfamide and their preparation: This invention provides stable, lyophilized formulations of canfosfamide as well as the methods of preparation of those stable lyophilized formulations.... Agent: Telik, Inc.

20120015893 - Formulations containing sorbitan carboxylic acid ester: The invention relates to formulations for the washing and care of human or animal body parts, said formulations containing sorbitan carboxylic acid esters and characterized in that the carboxylic acid part of the sorbitain carboxylic acid ester is derived from a carboxylic acid containing between 6 and 10 carbon atoms... Agent: Evonik Goldschmidt Gmbh

20120015894 - Aqueous hair cleansing agent: An aqueous hair cleansing agent contains a sulfate-type anionic surfactant having a specific structure, an ether carboxylate-type anionic surfactant having a specific structure, and an organic carboxylic acid or salt thereof, thereby has a pH of 1 to 5 at 25° C. when diluted 20-fold with water.... Agent: Kao Corporation

20120015896 - Anti-penicillin resistant pneumococci agent and novel 16-membered macrolide derivative:

20120015895 - Use of rr/sr-ractopamine: A method of promoting or improving the feed efficiency and the muscle-to-fat ratio in animals by administering to the animals a therapeutically effective amount of a mixture of RR-ractopamine and SR-ractopamine is disclosed. Manufacturing methods for making RR/SR-ractopamine are presented.... Agent: Bridge Pharma, Inc.

20120015897 - Novel formulation for treating fungal infections: A novel formulation for treating fungal infections comprising Cholesterol containing Nanosomal Amphotericin B in a Saline Suspension... Agent: Lifecare Innovations Pvt. Ltd.

20120015898 - Compounds and methods for treatment of sickle cell disease or complications associated therewith: Compounds, compositions and methods are provided for treatment of sickle cell disease or a complication associated therewith, or graft versus host disease, in an individual. More specifically, the use of particular glycomimetics for the treatment is described.... Agent: Glycomimetics, Inc.

20120016006 - Compositions and methods for increasing cellular uptake of rnai via sid-1: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Systemic RNA Interference Defective-1 (SID-I) gene, and methods of using the dsRNA to inhibit expression of SID-1.... Agent: Alnylam Pharmaceuticals ,inc. A Corporation

20120016004 - Compositions for inhibiting gene expression and uses thereof: The inventors have examined the means for providing more efficacious gene expression blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of gene expression blocking molecules. These features include the presence of multiple 3′ ends and a linker at the 5′ ends. Surprisingly, these features... Agent: Idera Pharmaceuticals, Inc.

20120016008 - Isolated genomic polynucleotide fragments from the p15 region of chromosome 11 encoding human ribosomal protein l26 (ribo26): Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human ribosomal protein L26 (RIBO26) and methods of use.... Agent: Ryogen LLC

20120016009 - Optimized methods for delivery of dsrna targeting the pcsk9 gene: This invention relates to optimized methods for treating diseases caused by PCSK9 gene expression.... Agent:

20120016005 - Phagocytic cell delivery of rnai: The present invention provides a particulate delivery system for delivering an RNAi construct to phagocytic cells such as macrophages, comprising various configurations of a complex comprising a phagocytic cell-targeting moiety and an RNAi construct. The invention further provides methods of making the delivery system, and their uses, such as treating... Agent: Rxi Pharmaceuticals Corporation

20120016003 - Pot1 alternative splicing variants: The present invention provides methods and compositions for diagnosis and treatment of carcinomas with aberrant expression patterns of POT 1. The invention also provides methods of identifying compounds that may modulate the cellular expression of POT 1. The invention further provides methods for treating subjects suffering from or at risk... Agent: The Government Of The United States, As Represented By The Secretary, Department Of Health

20120016010 - Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach1) gene expression using short interfering nucleic acid (sina): The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of Bach1 gene expression and/or activity, and/or modulate a Bach1 gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic... Agent: Merck Sharp & Dohme Corp

20120016011 - Rna interference mediated inhibition of connective tissue growth factor (ctgf) gene expression using short interfering nucleic acid (sina): The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of CTGF gene expression and/or activity, and/or modulate a CTGF gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic... Agent: Merck Sharp & Dohme Corp.

20120016012 - Rnai molecule targeting thymidylate synthase and application thereof: This invention provides a novel RNAi molecule that can significantly potentiate antitumor effects of a 5-FU antitumor agent. The RNAi molecule comprises the nucleotide sequence shown in SEQ ID NO: 2. The invention also provides an antitumor agent comprising such RNAi molecule and a 5-FU antitumor agent.... Agent:

20120016007 - Small interference rna complex with increased intracellular transmission capacity: A multiplex siRNA complex and a multifunctional nucleic acid structure complex, which have enhanced intracellular delivery capacity are provided. The siRNA complex and the multifunctional nucleic acid structure complex have a novel structure which can be chemically synthesized in an easy manner for a conventional shRNA system for inhibiting the... Agent:

20120016013 - Anti-cancer oligodeoxynucleotides: It is disclosed herein that suppressive OD Ns are of use for preventing or delaying the formation of a tumor, reducing the risk of developing a tumor, treating a tumor, preventing conversion of a benign to a malignant lesion, or preventing metastasis. In some embodiments, methods are disclosed herein for... Agent: The United States Of America, As Represented By The Secretary, Department Of Health And Human

20120015899 - Modified plant virus particles and uses therefor: Aspects of the invention provide modified virus-like particles that are designed for therapeutic applications. In particular, aspects of the invention provide CCMV coat proteins that are modified to generate virus-like particles, including mosaic virus-like particles, that can package and/or deliver one or more diagnostic and/or therapeutic agents. The invention also... Agent: Aura Biosciences

20120015900 - Cobalamin taxane bioconjugates: The present invention is directed to methods and compositions including a taxane covalently bonded to the cobalt atom of a cobalamin. The composition can be delivered by any effective route, but is particularly useful as an oral anti-cancer or antiangiogenic compound. The anti-cancer/anti-angiogenic compound can be used in various chemotherapies... Agent: Osiris Therapeutics, Inc.

20120015901 - Methods and preparations for protecting critically ill patients: The present invention relates to a method of treating a life threatening condition in a critically ill human patient with a non-infectuous disorder, wherein the critically ill patient is a patient receiving enteral or parenteral nutrition, the method comprising the step of administering to said patient an autophagy inducing agent.... Agent: University Of Graz

20120015902 - Arabinoxylo-oligosaccharides useful against gastrointestinal infections: The present invention relates to the use of oligosaccharides derived from arabinoxylan for use in the prevention and treatment of gastrointestinal infection. More particularly the invention provides a method for preventing or reducing the gastrointestinal infection of a animal or human being with bacteria associated with gastroenteritis through the supplementation... Agent: Fugeia N.v.

20120015903 - Pharmaceutical composition for inhibiting increase of iga: The present invention discloses a pharmaceutical composition for inhibiting increase of immunoglobulin A (IgA) comprising β-glucan and a pharmaceutical acceptable carrier. The β-glucan is extracted from Saccharomyces Cerevisiae, and the effective dose of the β-glucan is 300-450 mg/70 kg of body weights/per day, preferably, 350-400 mg/70 kg of body weights/day.... Agent: Fu Jen Catholic University

20120015904 - Biomarkers for diagnosis of transient ischemic attacks: The present invention provides methods and compositions for diagnosing and predicting the risk and cause of transient ischemic attacks (TIA).... Agent: Regents Of The University Of California

20120015905 - Compounds for the prevention and treatment of cardiovascular diseases: The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.... Agent: Resverlogix Corp.

20120015906 - Uses of bortezomib in predicting survival in multiple myeloma patients: The present invention provides a method of predicting outcome of treatment for multiple myeloma based on determining certain cytogenetic anomalies and considering gene expression profiling risks. Also provided are statistical methods employed to define variables independently impacting outcomes. Further provided is method of treatment of myeloma patients.... Agent:

20120015907 - Furopyridine compounds and uses thereof: e

20120015908 - Synthesis and anticancer activity of aryl and heteroaryl-quinolin derivatives:

20120015909 - Mao-b inhibitors useful for treating obesity:

20120015910 - Synergistic fungicidal active substance combinations:

20120015911 - Method and compositions for treating amyloid-related diseases: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.... Agent: Bellus Health Inc.

20120015912 - Use of 2,5-dihydroxybenzene for the treatment of ocular diseases: The present invention relates to the use of a compound of Formula (IIV) or pharmaceutically acceptable salt or solvate, isomer or prodrug thereof in the manufacturing of a medicament for the treatment and/or prophylaxis of any of the diseases selected from the group consisting of macular degeneration, corneal neovascularization or... Agent: Action Medicines

20120015913 - Formulations of 14-epi-analogues of vitamin d: The present invention provides new formulations of 14-epi-analogues of vitamin D, such as inecalcitol, providing improved absorption profile.... Agent:

20120015914 - Formulations of 14-epi-analogues of vitamin d: The present invention provides new formulations of 14-epi-analogues of vitamin D, such as inecalcitol, providing improved absorption profile.... Agent: Hybrigenics Sa

20120015915 - Formulations of 14-epi-analogues of vitamin d: The present invention provides new formulations of 14-epi-analogues of vitamin D, such as inecalcitol, providing improved absorption profile.... Agent: Hybrigenics Sa

20120015916 - Method for treating secondary hyperparathyroidism in ckd: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin... Agent: Cytochroma

20120015917 - Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy: The present invention relates to a pharmaceutical kit comprising a plurality of oral dosage units which comprise a progestogen. The progestogen is levonorgestrel, norgestimate, norethisterone, drospirenone, dydrogesterone, trimegestone, dienogest, precursors thereof and mixtures thereof. The kit comprises an amount of progestogen equivalent to 30-500 mg of levonorgestrel, 1-40 mg of... Agent: Pantarhei Bioscience B.v.

20120015920 - Heterobicyclic metalloprotease inhibitors: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and... Agent: Alantos Pharmaceuticals Holding, Inc.

20120015918 - Lipolytic methods for regional adiposity: Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments... Agent: Lithera, Inc.

20120015921 - Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same: Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms.... Agent: Opko Health, Inc.

20120015919 - Therapies for treating cancer using combinations of cox-2 inhibitors and aromatase inhibitors or combinations of cox-2 inhibitors and estrogen receptor antagonists: Described herein are compositions and methods for using these compositions in the treatment of cancer, tumors, and tumor-related disorders in a subject.... Agent: Tragara Pharmaceuticals, Inc.

20120015923 - Use of andrographolide compounds for treating inflammation and airway disorders: We describe for the first time that andrographolide derivatives such as DDAG effectively reduced OVA-induced inflammatory cell recruitment into BAL fluid, IL-4, IL-5, IL-13 and eotaxin production, serum IgE synthesis, pulmonary eosinophilia, mucus hypersecretion and AHR in a mouse asthma model potentially via inhibition of NF-?B activity. Moreover, low dose... Agent: National University Of Singapore

20120015922 - Use of artemisinin derivatives for the treatment of asthma and chronic obstructive pulmonary disease (copd): Artesunate is a derivative of artemisinin isolated from a Chinese herb Artemisia annua L. It is used clinically for the treatment of malaria. We investigated potential anti-inflammatory actions of artemisinin derivatives. artemisinin derivatives significantly inhibited OVA-induced signs, symptoms and parameter of airway disorders Taken together, our results clearly demonstrate anti-inflammatory... Agent: National University Of Singapore

20120015924 - Spray-drying process: The process comprises delivering a spray solution comprising an active agent and a matrix material in an organic solvent to a spray-drying apparatus, atomizing the spray solution into droplets within the spray-drying apparatus to remove at least a portion of the organic solvent from the droplets to form a plurality... Agent:

20120015928 - Amido compounds and their use as pharmaceuticals: The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or... Agent: Incyte Corporation

20120015926 - Compounds for the treatment of inflammatory disorders: This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations... Agent:

20120015925 - Novel benzothiazepine and benzothiepine compounds: A pharmaceutical useful as a therapeutic agent and a preventive agent for hyperlipemia, and a pharmaceutical useful as a therapeutic agent and a preventive agent for hepatic disorders associated with cholestasis, particularly, primary biliary cirrhosis and primary sclerosing cholangitis, and a pharmaceutical useful as a therapeutic agent and a preventive... Agent: Asahi Kasei Pharma Corporation

20120015931 - Purine compounds selective for pi3k p110 delta, and methods of use: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and n are defined herein, compositions including the compounds and method of using the compounds to treat a disease or disorder mediated by the p110 delta isoform of PI3 kinase selected from immune disorders, cancer, cardiovascular disease,... Agent:

20120015932 - Pyrazole derivatives used as ccr4 receptor antagonists: Indazole compounds, processes for their preparation, intermediates usable in these processes, pharmaceutical compositions containing such compounds and their use in therapy.... Agent:

20120015933 - Spirocyclic nitriles as protease inhibitors: The invention relates to substituted carbo- and heterocyclic spiro compounds of the formula Ia which inhibit thiol proteases, to processes for their preparation and to the use thereof as medicaments.... Agent: Sanofi-aventis

20120015930 - Substituted imidazoheterocycle derivatives: wherein Y is chosen from —O—, —OCRgRh—, —CRgRhO—, —CRgRh—, —(CRgRh)2—, —NRi—, —CRgRhNRi— and —NRiCRgRh—. Also provided are pharmaceutically acceptable salts, acid salts, hydrates, solvates and stereoisomers of the compounds of formula I. The compounds are useful as modulators of cannabinoid receptors and for the prophylaxis and treatment of cannabinoid receptor-associated... Agent: Cara Therapeutics, Inc.

20120015927 - Crystalline forms of n-[2-[[(2,3-difluorophenyl)methyl]thio]-6--4-pyrimidinyl]-1-azetidinesulfonamide: There is provided crystalline forms of N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]1-azetidinesulfon-amide anhydrate. Such compounds/forms may be useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.... Agent:

20120015929 - Novel compounds as cannabinoid receptor ligands: e

20120015934 - Cyclopamine lactam analogs and methods of use thereof: The present invention relates to steroidal alkaloids useful in the treatment of hedgehog pathway related disorders, particularly cancer.... Agent: Infinity Discovery, Inc., A Massachusetts Corporation

20120015935 - Substituted tetrahydropyrazolo-pyrido-azepine compounds: The present invention relates to substituted tetrahydropyrazolo-pyrido-azepine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted tetrahydropyrazolo-pyrido-azepine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.... Agent: Arqule, Inc.

20120015936 - Substituted tetrahydronaphthalenes, method for the production thereof, and use thereof as drugs: The invention relates to substituted tetrahydronaphthalenes, to derivatives thereof, to physiologically acceptable salts thereof, to physiologically functional derivatives, to the production thereof, to drugs containing at least one substituted tetrahydronaphthalene according to the invention or derivative thereof, and to the use of the substituted tetrahydronaphthalenes according to the invention and... Agent: Sanofi

20120015937 - Kinase inhibitors and their uses: The present disclosure provides compounds that inhibit protein kinases, such as JAK, Axl, or Syk kinases, compositions comprising the compounds and methods of using the compounds to inhibit protein kinase and treat and/or prevent diseases associated with inappropriate kinase activity.... Agent: Rigel Pharmaceuticals, Inc.

20120015938 - 1,4-benzodiazepin-2-on derivatives: The present invention relates to a compound represented by a formula (I): wherein R1 represents a halogen atom or the like; R2 represents a hydrogen atom or the like; R3 and R4 each independently represents lower alkyl; R5 represents phenyl or the like; R6 represents a halogen atom or the... Agent: Msd K.k.

20120015939 - Topical treatment of neuropathic pain and methods of diagnosis: Alpha-2 adrenergic agonists such as clonidine may be used to treat the pain associated with painful diabetic neuropathy (PDN) only in a subset of these patients. Targeted nociceptors (pain fibers) must be functionally expressed in the skin in order for clonidine to have a therapeutic effect. Neuropathies associated with pain... Agent: Arcion Therapeutics, Inc.

20120015940 - Novel aminopyridine derivatives having aurora a selective inhibitory action: The present invention relates to a compound of Formula (I): wherein: n is 0 or 1; X is O or CH2; R1 is H or C1-2 alkyl; R2 is H or C1-3 alkyl; R3 and R4 are each independently H or C1-2 alkyl, where the alkyl may be substituted with... Agent:

20120015941 - Antibacterial amide and sulfonamide substituted heterocyclic urea compounds: The present invention provides novel amide and sulfonamide substituted heterocyclic urea compounds having useful antibacterial activity. Use of these compounds as pharmaceutical compositions and method of their production are also provided.... Agent: Crestone, Inc.

20120015942 - Substituted hydroxamic acids and uses thereof: wherein R1a, R1b, R1c, R2a, R2b, R2c, and R2d have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases... Agent: Millennium Pharmaceuticals, Inc.

20120015943 - Substituted hydroxamic acids and uses thereof: wherein R1, R1b, R2a, R2b, R2c, and R2d have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or... Agent: Millennium Pharmacuticals, Inc.

20120015944 - Tetrazole-substituted arylamides as p2x3 and p2x2/3 antagonists: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5, R6 R7 and R8 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the... Agent: Roche Palo Alto LLC.

20120015945 - Use of cb1 antagonists and/or inverse agonists for the preparation of drugs that increase motor neuron excitability: Use of a CB1 receptor antagonist and/or inverse agonist, preferably rimonabant, for the preparation of drugs useful for increasing motor neuron excitability in the cerebral cortex and/or in the brain stem and/or at the spinal level, as well as a method for increasing motor neuron excitability through the administration of... Agent: Fundacion Del Hospital Nacional De Pa

20120015946 - Insecticidal compounds: A compound of formula (I): wherein A1, A2, A3, A4, G1, R1, R2, R3, R4, R5a, R5b and R6 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal, nematicidal... Agent: Syngenta Crop Protection, LLC

20120015947 - Cyclic hydroxylamine as psychoactive compounds: c

20120015948 - Tablet composition: A water soluble effervescent disinfecting tablet comprises a chlorinated isocyanurate such as anhydrous sodium dichloroisocyanurate. The tablet also comprises an alkali metal bicarbonate such as sodium bicarbonate, an aliphatic carboxyl acid such as adipidic acid, and a dessicant base such as sodium carbonate. The tablet contains a masking agent, especially... Agent:

20120015949 - Composition and method of decreasing renal ischemic damage: A method of decreasing renal ischemic damage comprising a) identifying an organism having a kidney that is susceptible to renal ischemic damage from an ischemic event; and b) administering to the organism one or more than one effective dose of an agent prior to the ischemic event; where administering to... Agent: Loma Linda University

20120015950 - Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof: Compound corresponding to general formula (I): in which R2 is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C1-6-alkyl, C1-6-alkoxy or NR8R9 group; n is an integer equal to 1, 2 or 3 and m is an integer equal to 1 or 2; A is a covalent bond... Agent: Sanofi-aventis

20120015952 - Inhibitors of nf-kb: m

20120015951 - Polymorphs of brimonidine pamoate: A brimonidine pamoate polymorph exhibits characteristics disclosed herein. The polymorph is included in a composition, device, or implant for use in the treatment or control of elevated intraocular pressure or in the neuroprotection of components of a neurological tissue to prevent progressive degeneration of such components. In particular, such a... Agent:

20120015953 - Methods and compositions for the treatment of allergy: The present invention relates to compositions comprising an antagonist of the histamine H1 receptor and a compatible antagonist of the histamine H4 receptor. The antagonist compounds are selected to prevent the H4 receptor antagonist from interfering with the H1 receptor antagonist's suppression of acute phase allergic responses in a patient.... Agent:

20120015954 - Therapeutic agents useful for treating pain: wherein Ar1, A, R3, x, and m are as disclosed herein and Ar2 is a benzothiazolyl, benzooxazolyl, or benzoimidazolyl group or a pharmaceutically acceptable salt thereof (a “Benzoazolylpiperazine Compound”), compositions comprising a Benzoazolylpiperazine Compound, and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's... Agent: Purdue Pharma L.p.

20120015955 - F, g, h, i and k crystal forms of imatinib mesylate: The invention relates to the F-crystal form, G-crystal form, H-crystal form, I-crystal form and K-crystal form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, certain processes for their preparation, pharmaceutical compositions containing these crystal forms, their use in diagnostic methods or for the therapeutic treatment of warm-blooded animals, and their... Agent:

20120015956 - Deuterium-enriched dasatinib: The present application describes deuterium-enriched dasatinib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Protia, LLC

20120015957 - Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor: The present invention is directed to piperidinyl and piperazinyl derivatives of formula (I) useful as inhibitors of the NPY Y2 receptor, pharmaceutical compositions comprising said compounds, processes for the preparation of said compounds and the use of said compounds for the treatment and/or prevention of disorders, diseases and conditions mediated... Agent:

20120015958 - 1-(4-ureidobenzoyl)piperazine derivatives: The present invention relates to 1-(4-ureidobenzoyl)piperazine derivatives having the general Formula I (We bring to your attention that formula I is not provided on this electronic version as it is provided in the abstract of the paper copy) Wherein R1 is (C1-8)alkyl, (C3-8)cycloalkyl or (C3-8)cycloalkyl(C1-3)alkyl, each of which may be... Agent:

20120015959 - Heterocyclic compounds as autotaxin inhibitors: Compounds of the formula (I), in which Het, R, X, Y, R1 and p have the meanings indicated in claim 1, are autotaxin inhibitors and can be employed for the treatment of tumours.... Agent:

20120015960 - Chemical inhibitor of p53-snail binding and pharmaceutical composition for treating cancer disease containing same as its active ingredient: Provided are compounds for inhibiting Snail-p53 binding and therapeutic agents for cancer including the compounds as an effective component. The Snail-p53 binding inhibitors induce expression of p53 in K-Ras mutant cell lines, thereby enabling effective treatment or prevention of K-Ras mutant cancer, such as, pancreatic cancer, lung cancer, cholangioma, and... Agent: Pusan National University Industry-university Cooperation Foundation

20120015961 - Isothiourea derivatives or isourea derivatives having bace1 inhibitory activity: o

20120015962 - Pyrazolo[1,5a]pyrimidine derivatives as irak4 modulators:

20120015963 - Novel pyrazolo[3,4-d]pyrimidine compounds: pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are as defined herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions,... Agent: Abbott Laboratories

20120015964 - Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta: Compounds that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compounds also are disclosed.... Agent: Icos Corporation

20120015965 - Pharmaceutical composition comprising n-[3-chloro-4-[(3-fluorophenyl)methoxy] phenyl]-6-[5[[[2-(methylsulfonyl) ethyl]amino]methyl]-2-furyl]-4- quinazolinamine: The present invention relates to a pharmaceutical composition comprising N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine as active pharmaceutical ingredient and a process of preparing such composition.... Agent: Ratiopharm Gmbh

20120015966 - Ppar active compounds: Compounds are described that are active on at least one of PPARα, PPARδ, and PPARγ, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPARα, PPARδ, and PPARγ.... Agent: Plexxikon Inc

20120015969 - Novel aminopyridine derivatives having aurora a selective inhibitory action: The present invention relates to a compound of Formula (I): wherein: R1 is H, —NHCOOR1a, C5-6 cycloalkyl, or phenyl; where the cycloalkyl and phenyl each independently may be substituted with one to three of the same or different substituents selected from R10; R1a is C1-3 alkyl which may be substituted... Agent:

20120015967 - Pyrimidine and pyridine derivatives as posh and posh-ap inhibitors: Pyridine and pyrimidine derivatives inhibit ubiquitination of human polypeptides, particularly of POSH and POSH-associated proteins such as HERPUD1, and can be used as medicaments for treatment of viral infections caused by virus such as HIV and for treatment of neurological disorders or diseases.... Agent: Proteologics, Ltd.

20120015968 - Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper-and sterile alpha motif-containing kinase (zak): wherein the radicals have the meanings as defined herein, or of a pharmaceutically acceptable salt thereof for the manufacture of pharmaceutical compositions for use in the treatment of disorders mediated by ZAK, to the use of a pyrimidylaminobenzamide derivatives of formula I or pharmaceutically acceptable salt thereof in the treatment... Agent: Novartis Ag

20120015970 - New azacyclic compounds: e

20120015971 - Ophthalmic composition comprising ascomycin: This invention relates to topical ophthalmic compositions comprising an ascomycin e.g. for the treatment of inflammatory diseases such as blepharitis.... Agent:

20120015972 - Indolizine derivative and use thereof for medical purposes: The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level and the like. That is, the present invention relates to indolizine derivatives represented by the following formula (I) having xanthine oxidase inhibitory activities and useful as agents... Agent: Kissei Pharmaceutical Co., Ltd.

20120015975 - Fused heterocyclic compound and use thereof: e

20120015974 - Imidazopyridine inhibitors of iap:

20120015973 - Mek mutations conferring resistance to mek inhibitors: The present invention relates to methods, compositions and kits concerning resistance to treatment with an anti-cancer agent, specifically an inhibitor of MEK. In particular embodiments, the invention concerns mutations in a MEK sequence that confer resistance to a MEK inhibitor. Identification of such mutations in a MEK sequence allows the... Agent: Dana-farber Cancer Institute, Inc.

20120015976 - Autotaxin inhibitors: The present invention relates to compounds according to formula (I) as autotaxin inhibitors and the use of such compounds for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of autotaxin, in particular of different cancers.... Agent: Merck Patent Gesellschaft Mit Beschrank Ter Haftung

20120015977 - Quinolinone derivatives useful for the treatment of cns disorders: The present invention relates to novel quinolinone derivatives (I), efficacious in animal models of CNS disorders and, as such, valuable candidates for the prevention or treatment of CNS (Central Nervous System) diseases or disorders. In other aspects the invention relates to pharmaceutical compositions comprising the quinolinone derivatives of the invention... Agent: Neurosearch A/s

20120015979 - Compounds for modulating trpv3 function: The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.... Agent: Hydra Biosciences, Inc,

20120015978 - Therapeutic agents for ocular hypertension: This invention provides well defined 6-alkyl or hydroxyalkyl-1-naphthamide or quinoline compounds for treating glaucoma or ocular hypertension.... Agent: Allergan, Inc.

20120015980 - Anthranilic diamide derivatives: i

20120015981 - Active compound combinations: The present invention relates to active compound combinations, in particular within a fungicide composition, which comprises (A) the compound 3-(difluoromethyl)-1-methyl-N-(3′,4′,5′-trifluorobiphenyl-2-yl)-1H-pyrazole-4-carboxamide of formula (I) and/or the compound 3-(difluoromethyl)-1-methyl-N-(2′.4′.5′-trifluorobiphenyl-2-yl)-1H-pyrazole-4-carboxamide of formula (II) and (B) at least one azolylmethyloxirane of formula (III). Moreover, the invention relates to a method for curatively or preventively... Agent: Bayer Corpscience Ag

20120015982 - Thiazolidinedione analogues: The present invention relates to thiazolidinedione analogues that are useful for treating metabolic inflammation mediated diseases such as diabetes.... Agent: Metabolic Solutions Development Company

20120015983 - Synthesis and novel salt forms of (r)-3-((e)-pyrrolidin-3-yl)vinyl)-5-tetrahydropyran-4-yloxy)pyridine: The present invention relates to (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine, its salt forms, and to processes for the commercial-scale production of these compounds in sufficient purity and quality for use in pharmaceutical compositions.... Agent: Targacept, Inc.

20120015984 - Granulate formulation of pirfenidone and pharmaceutically acceptable excipients: A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient... Agent: Intermune, Inc.

20120015985 - Methods of administering pirfenidone therapy: The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.... Agent: Intermune, Inc.

20120015986 - Salts of dehydroacetic acid as a pyrithione stabilizer in plastics: The invention provides a method for preventing discoloration of pyrithione-containing materials, in particular plastic materials or other material such as paints, coatings, adhesives or textiles which are exposed to an outdoor environment. The method is likewise suited for preventing discoloration of other pyrithione-containing materials such as personal care compositions like... Agent:

20120015987 - Novel polymorph of atazanavir sulfate: The present invention provides a novel crystalline form of atazanavir sulfate, process for its preparation and to pharmaceutical composition containing it. In accordance with the present invention atazanavir sulfate was dissolved in methanol, to the solution was added ethyl acetate, the solid obtained was collected by filtration and dried to... Agent: Hetero Research Foundation

20120015989 - Linked myc-max small molecule inhibitors: Provided herein are compounds and compositions for interfering with the association of Myc and Max. These compounds and compositions are useful in methods for inhibiting growth or proliferation of a cell. Methods of inhibiting growth or proliferation of a cell comprise contacting the cell with an amount of a compound... Agent:

20120015991 - Polycyclic antagonists of lysophosphatidic acid receptors: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.... Agent: Amira Pharmaceuticals, Inc.

20120015988 - Sulfone compounds which modulate the cb2 receptor: Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.... Agent: Boehringer Ingelheim International Gmbh

20120015990 - Taspase1 inhibitors and their uses: Provided herein are small molecule inhibitors of Taspase1 and methods of using the small molecule inhibitors of Taspase1 to treat neoplasm in subjects in need thereof.... Agent: The Washington University

20120015992 - Napthalene-based inhibitors of anti-apoptotic proteins: o

20120015993 - Novel pharmaceutical forms, and methods of making and using the same: Crystalline salts, polymorphs, solvates, and hydrates of bicalutamide, 5-fluorouracil, donepezil, anastrozole, nelfinavir, mirtazapine, lansoprazole, and tamsulosin, or derivatives thereof are provided by the subject invention. Methods of making and using the same are also provided.... Agent: Transform Pharmaceuticals, Inc.

20120015994 - (2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors: y

20120015995 - Bendamustine anionic-catioinic cyclopolysaccharide compositions: The present invention is directed to pharmaceutical compositions including: (a) bendamustine, (b) a first charged cyclopolysaccharide, and (c) a stabilizing agent which is a second charged cyclopolysaccharide having a charge opposite to that of the first charged cyclopolysaccharide. The composition provides unexpectedly desirable stability in reactive environments such as plasma,... Agent:

20120015996 - Antifungal medicinal compositions: An object of the present invention is to provide a medicinal composition useful for external application in the treatment of a fungal infection reaching the lower part of a thick keratin layer. Provided is an antifungal medicinal composition, comprising: (1) a film-forming agent; (2) a water-soluble plasticizer in a form... Agent: Pola Pharma Inc.

20120015997 - Pharmaceutical composition for external use: Provided is a pharmaceutical composition for external use, including: (i) a compound represented by structural formula (2) and/or a salt thereof; and (ii) N-methyl-2-pyrrolidone.... Agent: Nihon Nohyaku Co., Ltd.

20120015998 - Phototherapy methods and devices comprising emissive aryl-heteroaryl compounds: Disclosed herein are compounds represented by a formula: R1—Ar1—X—Ar2—Ar3-Het, wherein R1, Ar1, X, Ar2, Ar3, and Het are described herein. Compositions and light-emitting devices related thereto are also disclosed.... Agent: Nitto Denko Corporation

20120015999 - Formulations of (r)-1-(2,2-difluorobenzo[d] [1,3] dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide: The present invention relates to formulations of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1), pharmaceutical packs or kits thereof, and methods of treatment therewith.... Agent: Vertex Pharmaceuticals Incorporated

20120016000 - Method to assay phospholipid and triglyceride transfer activity of microsomal triglyceride transfer protein: The present invention is directed to a method for identifying an antagonist compound of microsomal triglyceride transfer protein (MTP), wherein the antagonist at least partially inhibits triglyceride transfer activity while not significantly inhibiting phospholipids transfer activity of MTP. In particular, the present invention is directed to assays for phospholipid (PL)... Agent:

20120016001 - Succinimide derivatives as ocular hypotensive agents: The present invention provides methods and pharmaceutical compositions for treating ocular disorders associated with elevated intraocular pressure, such as glaucoma, by administering antiepileptic or anti-convulsant compounds of the succinimide family, in particular compounds of formula I and/or II as defined herein.... Agent:

20120016002 - Patient selection and therapeutic methods using markers of prostaglandin metabolism: Disclosed herein are methods related generally to a patient selection process for identifying individuals for treatment of cancer, inflammation, pain, and/or related conditions.... Agent: Tragara Pharmaceuticals ,inc.

20120016014 - Benzothiophene carboxamide compounds, composition and applications thereof: s

20120016015 - Aldehyde conjugated flavonoid preparations: There is provided a method of conjugating a polymer containing a free aldehyde group with a flavonoid in the presence of an acid catalyst, such that the polymer is conjugated to the C6 or C8 position of the flavonoid A ring. The resulting conjugates may be used to form delivery... Agent: Agency For Science, Technology And Research

20120016016 - Methods and compositions for treating complications of diabetes and vascular diseases using flavones: Disclosed herein, inter alia, are methods and compositions for treating a complication of diabetes or a vascular disease using a 5-desoxy-flavone and/or 5-desoxy-flavonol.... Agent: The Salk Institute For Biological Studies

20120016018 - Composition for inducing multiple nuclear division of cells: s

20120016017 - Pharmaceutical composition for treating or preventing cancer: or a pharmaceutically acceptable salt thereof, and a process for preparing said compound of the formula I. The invention also relates to the use of a composition comprising said compound of the formula I or a pharmaceutically acceptable salt thereof as an active ingredient, for treating or preventing cancers.... Agent:

20120016019 - Pharmaceutical composition for treating or preventing cancer: or a pharmaceutically acceptable salt or hydrate thereof, and a process for preparing said compound of the formula I. The invention also relates to the use of a composition comprising said compound of the formula I or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient, for treating... Agent:

20120016020 - Solid dispersion of alpha-ketoamide derivatives: A solid dispersion comprising ((1S)-1-((((1S)-1-benzyl-2,3-dioxo-3-(cyclopropylamino)propyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester made amorphous in the presence of a water-soluble cellulosic polymer has improved storage stability. The solid dispersion also has improved solubility for an improved bioavailability.... Agent: Senju Pharmaceutical Co., Ltd.

20120016021 - Methods of treating fragile x syndrome, down's syndrome, autism and related disorders: Disclosed herein are methods of treating fragile X syndrome, fragile X-associated tremor/ataxia syndrome, Down's syndrome and other forms of mental retardation, and/or autism comprising administering a GABAB agonist prodrug to a subject suffering therefrom. The GABAB agonist prodrugs can be compounds of Formula (I), (II) or (III) as disclosed herein.... Agent: Xenoport, Inc.

20120016022 - Agrochemical composition for pest control and pest control method: The agrochemical composition for pest control comprises a propylene glycol fatty acid monoester and fenbutatin oxide in a proportion of 1:150 to 150:1 in terms of a mass ratio (propylene glycol fatty acid monoester:fenbutatin oxide). The pest control method comprises applying the propylene glycol fatty acid monoester and fenbutatin oxide... Agent: Ishihara Sangyo Kaisha, Ltd

20120016023 - Combination of selected opioids with muscarine antagonists for treating urinary incontinence: Active compound combinations of compounds of group A, particularly opioids such as (+)-(2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol or a salt thereof with a physiologically tolerated acid, and compounds of group B, particularly anti-muscarine agents such as oxybutynin or a salt thereof with a physiologically tolerated acid suitable for treatment of an increased urge to... Agent: Gruenenthal Gmbh

20120016024 - Water-in-oil emulsion composition: The present invention provides a water-in-oil emulsion composition that provides a post-application elastic feeling, softness, and a moisturizing effect and that is excellent in emulsion stability while it is a composition with a high internal-aqueous-phase proportion, which allows the makeup to stay on nicely because of its uniform applicability and... Agent: Shiseido Company, Ltd.

20120016025 - Perhydrolases for enzymatic peracid generation: Disclosed herein are variants enzymes that are structurally classified as CE-7 enzymes and have perhydrolysis activity. Also disclosed herein is a process for producing peroxycarboxylic acids from carboxylic acid esters using the aforementioned variant enzymes as well as methods and compositions comprising the variant enzymes. Further, disinfectant formulations comprising the... Agent:

20120016027 - Composition and method for improved lens comfort: The present invention relates to methods of preventing ocular discomfort, improving ocular comfort or ameliorating decrease in ocular comfort during wearing of an ophthalmic device (such as a contact lens), that include the administration of compositions comprising fatty acids, such as omega-3 and/or -6 fatty acids. The present invention also... Agent: Brien Holden Vision Institute

20120016026 - Compositions containing non-polar compounds: Provided are compositions and methods for producing stable foods and beverages that contain high concentrations of additives such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols and carotenoids; oil soluble vitamins; alpha lipoic acid; other oils; and... Agent:

20120016028 - Method of preparing an unsaturated fatty acid dry concentrate: There is provided a method of preparing an unsaturated fatty acid dry concentrate, wherein a substance comprising at least one unsaturated fatty acid is applied on a biologically inert matrix having a large surface area and is subsequently dried, as well as a composition comprising at least one unsaturated fatty... Agent: Vis-vitalis Lizenz-und Handels Gmbh

20120016029 - Antagonists of prostaglandin d2 receptors: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.... Agent: Panmira Pharmaceuticals, LLC

20120016030 - Methoxypolyethylene glycol thioester chelate and uses thereof: The present invention is directed generally to protecting cells, tissues and organs against the damaging effects of ionizing or other damaging agents associated with radiation or chemotherapy, or degenerative diseases or processes of various organs that elicit the production of free radicals or oxidants such as peroxides, superoxide anions, hydroxyl... Agent: Eastern Virginia Medical School

20120016031 - Biphenyl compound selective agonists of gamma rar receptors: e

20120016032 - Cosmetic composition containing calcium citrate and n-acylated aminoalcohol derivative to prevent dry skin and signs of cutaneous ageing: Provided is a method of treating aged skin, comprising topically applying to the aged skin a composition comprising a compound of Formula (I) in an amount effective to provide an anti-ageing effect. The compound of Formula (I) is used to prevent skin and/or to help to maintain or improve moisture... Agent: CognisIPManagement Gmbh

20120016033 - Small molecule antagonists of phosphatidylinositol-3,4,5-triphosphate (pip3) and uses thereof: Disclosed are new members of a class of non-lipid small molecule inhibitors which interfere with the interaction between phosphoinositol-3,4,5-triphosphate (PIP3) and pleckstrin homology (PH) domains. These molecules target a broad range of PIP3-dependent signaling events in vitro and exert significant anti-tumor activity in vivo, with improved activity and selectivity toward... Agent: Tufts University

20120016034 - Polymorphic form of n-(s)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof: Disclosed herein, in certain embodiments, is a crystalline polymorph form A of N-(S)-(3,4-difluoro-2 -(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide. Further disclosed herein, in certain embodiments, are pharmaceutical compositions comprising the crystalline polymorph form A of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl) -1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide.... Agent:

20120016035 - Synergistic combinations comprising a renin inhibitor for cardiovascular diseases: s

20120016036 - Material and methods for treating developmental disorders including comorbid and idiopathic autism: Subjects who were diagnosed with either comorbid or idiopathic autism were treated with acamprosate. Patients generally showed marked improvements in primary outcomes as assessed using, for example, standard clinic measures for functionality including the Clinical Global Impressions Improvement (CGI-I) and the Clinical Global Impressions Severity (CGI-S) scales.... Agent: Indiana University Research & Technology Corporation

20120016037 - Method for prevention and treatment of alzheimers: Elderly individuals are administered dosages of Trans-resveratrol totaling between about 250 mg and 1 gram per day. Typically about 500 mg of Trans-resveratrol are orally administered to such individuals on a daily basis. As a result of the chemical action of Trans-resveratrol in the bodies of the subjects, Alzheimer's disease... Agent:

20120016038 - Compositions and methods for altering the rate of hydrolysis of cured oil-based materials: Disclosed herein is the correlation of chemical properties of oils with the physical properties of a resulting cured oil composition. Also disclosed are biocompatible materials and coatings for medical devices prepared using enriched oils and methods for enhancing or modifying the physical and chemical characteristics of cured oils by enriching... Agent:

20120016039 - Use of olive-oil-derived compounds as surfactants: The use of—olive-oil—derived compounds as surfactants is described, wherein such olive-oil-derived compounds are obtained by olive oil transesterification. Preferably, such compounds are a mixture-composed of an emollient and of anionic surfactants. As an emollient a product obtained via transesterification of olive oil with glycerine derivatives is preferably used most preferably... Agent: B & T S.r.l.

  
01/12/2012 > 181 patent applications in 135 patent subcategories. recently filed with US Patent Office

20120010123 - Methods of treating metabolic disorders and cardiovascular diseases: A method of treating an LCN13-related condition is provided comprising administering to a patient in need thereof a therapeutically effective amount of a lipocalin or a physiologically active fragment thereof.... Agent: The Regents Of The University Of Michigan

20120010124 - Cell penetrating peptide conjugates for delivering of nucleic acids into a cell: The invention provides cell penetrating peptide-nucleic acid conjugates having the formula P-L-N, wherein P is a cell penetrating peptide, N is a nucleic acid, preferably an oligonucleotide and more preferably a siRNA, and L is a hydrophilic polymer, preferably a polyethylene glycol (PEG)-based linker linking P and N together. Compositions,... Agent: Diatos

20120010125 - Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders: e

20120010126 - Recombinant surfactant protein d compositions and methods of use thereof: We describe an rspd(n/CRD) polypeptide, fragment, homologue, variant or derivative thereof for use in a method of treatment or prophylaxis of a disease. A method of treating an individual suffering from a disease or preventing the occurrence of a disease in an individual is also described, in which the method... Agent: Medical Research Council

20120010127 - Compositions comprising multiple bioactive agents, and methods of using the same: In part, the present invention is directed to compositions comprising a FabI inhibitor and at least one other bioactive agent. In another part, the present invention is directed to antibacterial compositions comprising a compound of formulas I-III and at least one other antibacterial agent.... Agent:

20120010128 - Antifungal paints and coatings: Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compostions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building... Agent: Reactive Surfaces, Ltd. LLP

20120010129 - Antifungal paints and coatings: Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compostions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building... Agent: Reactive Surfaces, Ltd. LLP

20120010130 - Composition for preventing virus infection comprising poly-gamma-glutamic acid: t

20120010131 - Novel cyclosporin analogues:

20120010132 - Methods for treating progressive cognitive disorders related to neurofibrillary tangles: The described invention provides methods for treating or preventing progression of a progressive cognitive disease, disorder or condition, and methods for improving resilience of cognitive function in a subject in need thereof.... Agent:

20120010133 - Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent: Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperazine-insulin formulation. The dry powders have utility as pharmaceutical formulations for... Agent: Mannkind Corporation

20120010134 - Soluble non-depot insulin conjugates and uses thereof: In one aspect, the disclosure provides a conjugate comprising an insulin molecule having an A-chain and a B-chain; an affinity ligand covalently bound to the A-chain; and a monovalent glucose binding agent covalently bound to the B-chain, wherein the affinity ligand competes with glucose for non-covalent binding with the monovalent... Agent:

20120010135 - Spiro derivatives for the modulation of stearoyl-coa desaturase: The present invention provides spiro derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.... Agent: Novartis Ag

20120010136 - Use of cd31 peptides in the treatment of thrombotic and autoimmune disorders: The present invention stems from the finding that the extracellular domain of CD31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of CD31. The invention relates to peptides corresponding to fragments of CD31 that inhibit T-cell response, and to their use in... Agent:

20120010137 - Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer: The invention provides methods for treatment of tissue factor (TF) mediated or associated diseases or processes, such as cancer, by administering at least an active fragment of an Ixolaris polypeptide to a subject. The invention further includes identification of a subject in need of such treatment, and monitoring a subject... Agent:

20120010138 - Novel uses of vegfxxxb: The invention provides VEGFxxxb, or an agent which selectively promotes the expression of VEGFxxxb in preference to VEGFxxx in cells of a subject or in vitro, or an expression vector system which causes the expression of the VEGFxxxb in a host organism, for use in treating or preventing microvascular hyperpermeability... Agent:

20120010139 - Thermal responsive composition for treating bone diseases: e

20120010140 - Self-assembling peptides for regeneration and repair of neural tissue: The present invention provides methods and compositions for enhancing regeneration and/or repair of neural tissue. One method include providing a nanoscale structured material at the site of injury, wherein the nanoscale structured material provides an environment that is permissive for regeneration of neural tissue and allows axon growth from a... Agent: Massachusetts Institute Of Technology

20120010141 - Method for stimulating wound healing: The present invention relates to a method for stimulating wound healing, and more particularly to a method for stimulating wound healing in a subject in need thereof, comprising administering to a wound of the subject an effective amount for stimulating wound healing of a composition, wherein the composition comprises p43... Agent: Atyr Pharma, Inc.

20120010142 - Natriuretic activities: This document provides methods and material related to natriuretic polypeptides. For example, substantially pure polypeptides having a natriuretic peptide activity, nucleic acids encoding polypeptides having a natriuretic peptide activity, host cells containing such nucleic acids, and methods for inducing a natriuretic or diuretic activity within a mammal are provided.... Agent:

20120010143 - Adhesive hemostatic agent based on porcine atelocollagen and method for production thereof: Disclosed is an adhesive hemostatic agent based on non-blood constituents including DOPA, able to strongly adhere to collagen fibers, and which comprises an antifibrinolytic agent in addition to an esterified atelocollagen which is non-immunogenic and may become positively charged thereon such that the adhesive hemostatic agent has no possibility of... Agent: Dalim Biotech Co., Ltd.

20120010144 - Peg-albumin composition having at least one protected thiol region as a platform for medications: This composition comprises a polyethylene glycol-albumin composition having at least one protected thiol region wherein the composition comprises PEG-AlbCys34 with Cys-34 preserved as a thiol. The albumin is linked to medications such as, antioxidants with a reduced sulfhydryl group through the Cys 34 residing on the albumin. The compositions are... Agent:

20120010145 - Methods and compositions for delivery of medicaments to the lungs: The disclosure provides a drug composition formulated for inhalation comprising a conjugate of a surface active agent and a pulmonary active drug. The surface active agent has an affinity for the human alveolar/gas interface and comprises at least a portion of a mammalian lung surfactant of a mimic thereof. The... Agent:

20120010146 - Composite containing collagen and elastin as a dermal expander and tissue filler: An injectable composition having dermal filling and tissue expanding activity comprises (1) a quantity of elastin sufficient to bring about dermal filling and tissue expansion when injected into a subject in need of dermal filling and tissue expansion, and (2) a pharmaceutically acceptable carrier. The composition can further comprise collagen,... Agent: Hancock Jaffe Laboratories, Inc.

20120010147 - Nmdar biomarkers for diagnosis and treatment of traumatic brain injury and other disorders: Provided are methods for detecting various subunits and isoforms of NMDA receptors to help diagnose and differentiate (1) the anatomical location of NMDA receptor over-expression. (2) ischemic conditions in the central and peripheral nervous systems, and (3) the type and cause of chronic pain.... Agent: Grace Laboratories, LLC

20120010148 - Combination therapies using nap: This invention relates to treatment of neurodegeneration, multiple sclerosis, or schizophrenia using an ADNF III polypeptide in combination with another therapeutic agent. Neurodegeneration, including neurodegeneration caused by dementia-related conditions, such as tauopathies, including Alzheimer's disease, and aging-related dementia, is treated by a combination of an ADNF III polypeptide and an... Agent: Ramot At Tel Aviv University Ltd.

20120010150 - Lactoferrin compositions and methods of wound treatment: The present invention relates to lactoferrin compositions and methods of using the compositions to treat wounds. The compositions can be administered alone or in combination with other standard wound healing therapies.... Agent:

20120010149 - Peptide combination: The invention relates to a peptide combination characterized by peptides each having the same sequence length (SEQL), that can be produced from a mixture (A) comprising a number x of amino acids having a protected acid group or a number z of peptides having an acid group protected by means... Agent: Gkl-biotec Ag

20120010152 - Targeting of podoplanin with lectin for use in the prevention and treatment of cancer: Lectin compositions and methods for reducing tumor cell growth and preventing or treating cancer are provided.... Agent: University Of Medicine And Dentistry Of New Jersey

20120010151 - Use of wnt5-a peptide derivates for the treatment of melanoma and gastric cancer: The present invention relates to a novel unbranched carbamate derivative, in particular N-butyloxycarbonyl derivative of certain Wnt5-α peptides and to their use in the treatment of melanoma or gastric cancer, as well as a method for treating melanoma as well as a pharmaceutical composition comprising the same derivative.... Agent:

20120010154 - Cytotoxic conjugates having neuropeptide y receptor binding compound: There is provided a series of novel neuropeptide Y-cytotoxic conjugates, compositions comprising the same, and methods relating to their therapeutic use for the treatment of disease or condition states associated with aberrant or undesirable proliferation of cells that express NPY-Y1 receptors.... Agent:

20120010153 - Novel tumor-targeting compounds: The invention relates to a novel compounds targeting human cancer cells, a method for synthesis of such compounds, and use of such compounds in treating cancer.... Agent:

20120010155 - Gntiii expression in plants: The invention relates to the field of glycoprotein processing in transgenic plants used as cost efficient and contamination safe factories for the production of recombinant biopharmaceutical proteins or pharmaceutical compositions comprising these glycoproteins. The invention provides a plant comprising a functional mammalian enzyme providing mammalian GnTIII that is normally not... Agent:

20120010156 - Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Delta-like (1) homolog (DLK1), in particular, by targeting natural antisense polynucleotides of Delta-like (1) homolog (DLK1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders... Agent: Opkp Curna, LLC

20120010157 - Method of stimulating the motility of the gastrointestinal system using ipamorelin: The present invention provides a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders, diseases, conditions, or drug- or surgery-induced dysfunction) of the gastrointestinal system, by administering to the subject a ghrelin mimetic, or pharmaceutically acceptable... Agent: Helsinn Therapeutics (u.s.), Inc.

20120010159 - Combination therapies with cox-2 inhibitors and treprostinil: The present invention is directed to compositions and methods for pain management, and for treating inflammation or an inflammation-associated disorder in a subject comprising administering to the subject a therapeutically effective amount of a COX-2 inhibitor and a therapeutically effective amount of a prostacyclin analog, such as treprostinil, a pharmaceutically... Agent: United Therapeutics Corporation

20120010158 - Tumor necrosis factor inhibiting peptides and uses thereof: The present invention relates to Tumor Necrosis Factor-alpha (TNF-alpha or TNF-α) inhibiting peptides and process for the preparation thereof. The present invention further relates to a pharmaceutical composition comprising TNF-alpha inhibiting peptides of the present invention and uses thereof in treating TNF-alpha mediated inflammatory disorders.... Agent: Panacea Biotec Ltd.

20120010160 - Rapidly dissolving oral strip of sugar for hypoglycemia: A method of orally administering measured doses of sugar into the bloodstream for controlling glucose levels, particularly for those individuals with diabetes or those who experience difficulty maintaining healthy blood sugar levels. The method comprises providing packets of orally ingestible strips of a disintegrating matrix containing a dose of sugar... Agent:

20120010161 - Novel azapeptide or azapeptidomimetic compounds inhibiting bcrp and/or p-gp: m

20120010162 - Method for treatment of lung infections by administration of aminoglycosides by aerolisation: The present invention regards a novel administration form and a novel administration regime useful in the treatment and prevention of a bacterial lung infection in patient in need thereof, in particular by providing a composition useful for aerosolization of a highly concentrated solution of aminoglycosides such as Tobramycin.... Agent: Xellia Pharmaceuticals Aps

20120010163 - Novel antibacterial compounds, methods of making them, and uses thereof: The present invention relates to novel therapeutics with antibacterial activity, processes for their preparation, and pharmaceutical, veterinary and nutritional compositions containing them as active ingredients. The present invention also relates to uses of the novel therapeutics, for example, as medicants or food additives in the treatment of bacterial infections or... Agent: Albany Molecular Research, Inc.

20120010268 - Isolated genomic polynucleotide fragments from the p15 region of chromosome 11 encoding human achaete-scute homolog 2 (hash2): Provided herein are isolated genomic polynucleotide fragments from the p15 arm of chromosome 11 encoding HASH2 and methods of use.... Agent: Ryogen LLC

20120010269 - Isolated genomic polynucleotide fragments from the p15 region of chromosome 11 encoding human sms3: Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human SMS3 (SMS3) and methods of use.... Agent: Ryogen LLC

20120010270 - Isolated genomic polynucleotide fragments from the p15 region of chromosome 11 encoding human tumor suppressing subtransferable candidate 6 (tssc6): Provided herein are isolated genomic polynucleotide fragments from the from the p15 region of chromosome 11 encoding human tumor suppressing subtransferable candidate 6 and methods of use.... Agent: Ryogen LLC

20120010272 - Rna interference mediated inhibition of apoptosis signal-regulating kinase 1 (ask1) gene expression using short interfering nucleic acid (sina): The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of ASK1 gene expression and/or activity, and/or modulate a ASK1 gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic... Agent: Merck Sharp & Dohme Corp.

20120010267 - Rnai modulation of mll-af4 and uses thereof: The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides.... Agent:

20120010271 - Single-stranded nucleic acid molecule for controlling gene expression: Provided is a novel nucleic acid molecule that can inhibit the expression of a gene and can be produces easily and efficiently. The nucleic acid molecule is a single-stranded nucleic acid molecule including an expression inhibitory sequence that inhibits expression of a target gene. The single-stranded nucleic acid molecule includes,... Agent: Bonac Corporation

20120010266 - Tbc1d7 as tumor marker and therapeutic target for cancer: The present invention relates to the roles played by the TBC1D7 genes in cancer, in particular, lung cancer or esophageal cancer, or carcinogenesis and features a method for treating and/or preventing cancer, in particular, lung cancer or esophageal cancer by administering a double-stranded molecule against one or more of the... Agent: Oncotherapy Science Inc.,

20120010274 - Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a... Agent: Celera Corporation

20120010273 - Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor: The present invention relates to a hybrid Hepatocyte Growth Factor (HGF) gene which is prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has a base sequence of SEQ ID NO: 2. The gene has high expression efficiency and simultaneously expresses two... Agent: Viromed Co., Ltd.

20120010275 - Isolated genomic polynucleotide fragments from the p15 region of chromosome 11: Provided herein are isolated genomic polynucleotide fragments from the p15 arm of chromosome 11 and methods of use.... Agent: Ryogen LLC

20120010276 - Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3): The present invention provides materials and methods for screening for and treating hereditary lymphedema in human subjects.... Agent: Vegenics Pty Ltd

20120010164 - Antiviral agents: Compounds of structural formula (I): and pharmaceutically acceptable salts thereof; as defined herein, are described for use in the prevention and/or treatment of HCV infections. Novel compounds of the formula (I) and pharmaceutical formulations containing them are also described.... Agent:

20120010165 - Potentiator of radiation therapy: The invention provides a radiation therapy potentiator containing, as an effective ingredient, a uracil derivative represented by formula (1) (wherein R1 represents a halogen atom or a cyano group; and R2 represents a 4- to 8-membered heterocyclic group having 1 to 3 nitrogen atoms and optionally having as a substituent... Agent: Taiho Pharmaceutical Co., Ltd.

20120010166 - Stable iron oligosaccharide compound: The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided... Agent: Pharmacosmos Holding A/s

20120010167 - Countermeasure methods and devices: Embodiments of the present invention provide methods for protecting against toxic agents using chitosan formulations.... Agent:

20120010169 - Solubilized composition: b

20120010168 - Unique dual-action therapeutics: A new family of therapeutics which provides a controlled-release delivery platform for non-steroidal anti-inflammatory agents on an ester or an ester-carbonate backbone is disclosed herein. These agents are reversible inhibitors of acetylcholinesterase and are thus useful for clinical conditions benefiting from inflammation suppression and cholinergic intervention. These compounds are of... Agent:

20120010170 - \"methods of reducing nephrotoxicity in subjects administered nucleoside phosphonates\": A conjugate compound comprising an acyclic nucleoside phosphonate covalently coupled to a lipid for the therapeutic and/or prophylactic treatment of viral infection in an immunodeficient subject is described, along with compositions and methods of using the same. A preferred conugate compound is CMX001, having formula (I) or a pharmaceutically acceptable... Agent:

20120010171 - Nucleotide analogue prodrug and the preparation thereof: The present invention provides: 1) Derivative solid form of 9-[2-(R)-[bis[pivaloyloxymethoxy]-phosphinylmethoxy]propyl]adenine (bis-POM PMPA, abbreviated as TD hereinafter), including crystalline form A and form B of TD, TD fumarate salts and cyclodextrin inclusion complex of TD; 2) Synthesis and purification methods of TD and Solidification method of TD oil, including converting TD... Agent: Brightgene Bio-medical Technology Co., Ltd.

20120010172 - Novel urea and thiourea derivatives: The present application discloses compounds of formula (I) wherein X is ═O, ═S, ═NH, ═NOH and ═NO-Me; A is —C(═O)—, —S(═O)2—, —C(═S)— and P(═O)(R5)—; B is, —O—, —(CH2)3-6—, and O—(CH2)2-5—; D is, —O—, —CR7R8— and —NR9; m is 0-12, n is 0-12, m+n is 1-20; p is 0-4; R1 is... Agent: Mcdermott Will & Emery LLP

20120010173 - Fosfluconazole derivatives, synthesis, and use in long acting formulations: The invention relates to a compound of formula (I) and the salts, N-oxides, quaternary amines, and stereoisomers thereof, wherein R1 to R8 are as defined in the claims. The invention further relates to intermediates and methods for the preparation of the compounds of formula (I). The invention also relates to... Agent: Seps Pharma N.v.

20120010174 - Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin: The present invention relates to mixed calcium/sodium salt of inositol tripyrophosphate, methods of preparing and methods of use. The mixed calcium/sodium salt may be a monocalcium tetrasodium salt of inositol tripyrophosphate. Methods of use include administering the above salts in an effective amount to treat diseases caused by hypoxia or... Agent: Normoxys, Inc.

20120010175 - Process for preparing malathion for pharmaceutical use: The present invention provides a process for preparing a highly pure form of malathion having a reduced level of toxic impurities. In addition, the malathion prepared by the process of this invention is storage stable. The level of toxic impurities in the malathion, e.g., isomalathion, O,O,S-trimethyl phosphorodithioate (MeOOSPS), O,O,S-trimethyl phosphorothioate... Agent: Taro Pharmaceuticals North America, Inc.

20120010177 - Microrna modulators and method for identifying and using the same: The present invention is a method for identifying agents which modulate microRNA activity. The invention involves contacting a cell harboring a microRNA and a microRNA binding sequence, which is operably linked to a nucleic acid molecule encoding a reporter protein, with a test agent and determining whether the test agent... Agent: The Wistar Institute / North Carolina State University

20120010176 - Utrophin promoter activity upregulation for the treatment of muscular dystrophy: Methods are provided for increasing utrophin promoter activity, utrophin expression or utrophin activity, and treating or reducing the symptoms of muscular dystrophy by administering to a subject in need thereof an effective amount of a composition comprising a utrophin promoter or activity upregulator. Muscular dystrophy includes but is not limited... Agent:

20120010178 - Methods and compounds for treatment of neurodegenerative disorders: Methods, compounds and compositions for promoting motor neuron survival and the treatment of a neurodegenerative disorders such as Spinal Muscular Atrophy (SMA) are described herein.... Agent: President And Fellows Of Harvard College

20120010179 - Methods of using a thiazole derivative: This invention relates to a method of treating a disease, disorder, or condition in a patient comprising administering to a patient a therapeutically effective amount of a thiazole derivative, tetomilast. The invention further relates to the administration of at least one beta2-adrenergic receptor agonist, with tetomilast for treating a disease,... Agent:

20120010180 - Soluble dosage forms containing cephem derivatives suitable for parenteral administration: The present invention relates to new dosage forms of cephem compounds, useful for the treatment of bacterial infections. The dosage forms are stable, exhibit enhanced solubility, and are particularly well suited for, e.g., parenteral administration.... Agent: Forest Laboratories Holdings Ltd.

20120010181 - Compounds for the treatment of inflammatory disorders: This invention relates to compounds of the Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase,... Agent:

20120010189 - (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds: i

20120010190 - 1-hydroxyimino-3-phenyl-propanes:

20120010188 - Imidazopyridine compounds: The invention relates to compounds of formula (I): and their pharmaceutically acceptable salts and solvates, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment or prevention of medical conditions wherein inhibition of SSAO... Agent: Promimagen Ltd.

20120010187 - Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials: The invention provides FIG. 1 novel antimicrobial chemical entities based on a nitrothiazolide backbone that exhibit antibacterial and antiparasitic action against a wide range of human pathogens. The new classes of compounds show extended action against Gram positive bacteria including MRSA drug resistant pathogens. In the Gram-positive organisms, they specifically... Agent: University Of Virginia Patent Foundation

20120010182 - Chemical compounds: e

20120010183 - Chemical compounds:

20120010186 - Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase: Heterocyclic compounds of structural formula I are inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD). The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; obesity; diabetes; neurological disease; Metabolic Syndrome; insulin resistance; cancer, liver... Agent: Merck Frosst Canada Ltd.

20120010185 - New pyridone derivates with mch antagonistic activity and medicaments comprising these compounds: wherein the groups and radicals B, k, L, U, V, W, X, Y, Z, R1, R2, have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according... Agent: Boehringer Ingelheim International Gmbh

20120010184 - Therapeutic uses of compounds which selectively modulate the cb2 receptor: e

20120010193 - Cgrp receptor antagonists: Compounds of Formula (I) (wherein variables A1, A2, A3, ring-B, m, n, J, E1, E2, E3, R5, RPG and Y are as described herein), which are useful as antagonists of CGRP receptors, and useful in the treatment or prevention of diseases in which CGRP receptors are involved, such as headache,... Agent: Merck Sharp & Dohme Corp.

20120010192 - Fused heterocyclic compounds as ion channel modulators: m

20120010191 - Pyridone and aza-pyridone compounds and methods of use: Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis,... Agent: Gilead Connecticut, Inc.

20120010194 - 11-beta-hydroxysteroid dehydrogenase type 1 active compounds: The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, of the general formula I. Their use in therapy, pharmaceutical compositions comprising the compounds, as well as... Agent: High Point Pharmaceuticals, LLC

20120010195 - Imidazole derivatives: The present invention relates to novel imidazole derivatives of formula (I) having microbiocidal, in particular fungicidal, activity, to processes for their preparation and intermediates used in their preparation, to agrochemical compositions comprising them and to the use in agriculture or horticulture for controlling or preventing infestation of plants, harvested food... Agent: Syngenta Crop Protection, LLC

20120010196 - Methods of treating neurodegenerative disorders and diseases: This invention is directed to a novel method of treating neurodegenerative disorders and diseases. Another, related aspect of this invention is directed to a screening method of identifying compounds that can be used to treat neurodegenerative disorders and diseases. The foregoing aspects of the invention particularly relate to neurodegenerative disorders... Agent:

20120010198 - Methods for treating sleep disorders by cholecystokinin (cck) receptor b antagonists: The present invention relates to a method for preventing or ameliorating a sleep-related breathing disorder. The method involves the use of one or a combination of cholecystokinin (CCK) receptor antagonists.... Agent: The Board Of Trustees Of The University Of Illinois

20120010199 - Novel pyrrolinone derivative and pharmaceutical composition comprising the same: e

20120010197 - Protein kinase inhibitors:

20120010200 - Biaryl heterocyclic compounds and methods of making and using the same: The present invention relates generally to the field of anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. More particularly, the invention relates to a family of compounds having both a biaryl moiety and at least one heterocylic moiety that are useful as such agents.... Agent:

20120010201 - Novel anellated pyridine compounds: e

20120010202 - Polymerizable benzoxazine compounds with interfacial active or surface active properties: The invention relates to polymerizable benzoxazine compounds with interfacial active or surface active properties, having at least one polyalkylene oxide structural element, and to a method for producing said compounds. The invention also relates to benzoxazine (co)polymers comprising at least one of said benzoxazine compounds in the polymerized form.... Agent: Henkel Ag & Co. Kgaa

20120010203 - Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments: where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the... Agent: Sanofi-aventis

20120010204 - Phthalazinone derivatives: wherein A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X═NRX then n is 1 or 2 and if X═CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl,... Agent: Kudos Pharmaceuticals Limited

20120010205 - Novel quinoline esters useful for treating skin disorders: which are useful as Liver X receptors (LXR) modulators. Pharmaceutical compositions containing quinoline esters of Formula (I) and the use of quinoline esters of Formula (I) in the safe treatment of various skin disorders are also disclosed. Methods for preparing and using quinoline esters are further described.... Agent: Wyeth LLC

20120010206 - Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases: i

20120010207 - Chemical compounds:

20120010208 - 6-cycloamino-3-(1h-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof: The invention relates to 6-cycloamino-3-(1H-pyrrolo[2,3-b]pyridin-4-yl)imidazo[1,2-b]pyridazine derivatives corresponding to the general formula (I) in which R2 represents an aryl group optionally substituted with one or more halogen atoms or C1-6-alkyl, C1-6-alkyloxy, C1-6-alkylthio, C1-6-fluoroalkyl, C1-6-fluoroalkyloxy and —CN groups or R2 represents a group chosen from C1-6-alkyl, C1-6-fluoroalkyl, C3-7-cycloalkyl or C3-7-cycloalkyl-C1-6-alkyl groups; A... Agent: Sanofi

20120010209 - Imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines as mark inhibitors: The invention encompasses imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.... Agent:

20120010210 - L-methylfolate treatment for psychiatric or neurologic disorders: Provided herein are methods of treating neuropsychiatric disorders or improving the symptoms associated therewith administering a medical food, such as L-methylfolate, to a subject having the disorder. The neuropsychiatric disorder may be an autism spectrum disorder or attention deficit disorder with or without hyperactivity (ADD/ADHD). The L-methylfolate may be administered... Agent:

20120010211 - Pharmaceutical composition for treatment of type 2 diabetes: The present invention provides a pharmaceutical composition for the treatment of 2 type diabetes, wherein the pharmaceutical composition contains (R)-7-[3-amino-4-(2,4,5-trifluoro-phenyl)-butyryl]-3-trifluoromethyl-5,6, 7,8-tetrahydro-imidazo[1,5-a]pyrazine-1-carboxylic acid methyl ester or its pharmaceutically acceptable salts and metformin or its pharmaceutically acceptable salts (such as hydrochlorate), preparation method thereof and method of treating 2 type diabetes with... Agent: Jiangsu Hengrui Medicine Co., Ltd.

20120010212 - Methyl-pyrrolidine ether derivatives: wherein A is defined herein or to pharmaceutically active salts, stereoisomeric forms, including individual diastereoisomers and enantiomers of the compound of formula I as well as racemic and non-racemic mixtures thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia,... Agent:

20120010213 - Oral controlled release dosage forms for water soluble drugs: Disclosed herein is an oral controlled release pharmaceutical formulation comprising water-soluble drug or pharmaceutically acceptable salts thereof, in a hydrophilic matrix system, further comprising pH independent polymers present in an amount of 5% to 90% w/w in combination with acid insoluble polymer present in an amount of 1% to 70%... Agent: Fdc Limited

20120010214 - 3-(imidazolyl)-pyrazolo[3,4-b]pyridines: Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.... Agent: Chemocentryx, Inc.

20120010215 - Treatment of bacterial diseases of the respiratory organs: The invention relates to inhalable quinolonecarboxylic acid derivative compositions for local control of diseases of the respiratory organs, in particular of lung diseases.... Agent: Bayer Schering Pharma Aktiengesellschaft

20120010218 - Formulations: The present invention relates to pharmaceutical compositions for oral administration of active compounds.... Agent:

20120010217 - Non-sedating antihistamine injection formulations and methods of use thereof: Described herein are injectable compositions containing non-sedating or second and third generation antihistamines such as cetirizine/levocetirizine and methods of use thereof. Specifically, methods of treating acute urticaria or angioedema associated with an acute allergic reaction are disclosed. In certain embodiments, the injectable compositions are bioequivalent to currently marketed oral dosage... Agent:

20120010216 - Pharmaceutical compositions containing vanoxerine: Disclosed embodiments are related to compositions of vanoxerine (GBR 12909), including compositions of vanoxerine and one or more diluents, disintegrants, binders and lubricants, and the processes for their preparation thereof.... Agent:

20120010219 - Salvinorin derivatives and uses thereof: The invention features salvinorin compositions that are selective for kappa opioid receptors; methods of treating mania by using a selective kappa receptor agonist; and methods of treating mood disorders, such as depressive disorders and manic disorders, using salvinorin compositions.... Agent: The Mclean Hospital Corporation

20120010220 - Spiroindolinepiperidine derivatives: e

20120010221 - Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide: Disclosed is a useful tablet which contains a high quantity of 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof; has a size that is easy to ingest; has superior release characteristics; and has a hardness that can withstand film coating, packaging, and transportation.... Agent: Toyama Chemical Co.,ltd.

20120010222 - Gyrase inhibitors and uses thereof: The present invention relates to methods of treating, preventing, or lessening the severity of resistant bacterial infections in mammals, utilizing compounds of formula I or formula VII or pharmaceutically salts thereof. The present invention also relates to methods of using compounds of formula I or formula VII in combination with... Agent: Vertex Pharmaceuticals Incorporated

20120010223 - Isothiazolo-pyrimidinedione derivatives as trpai modulators: The present invention is related to novel isothiazolo[3,4-d]pyrimidinedione and isothiazolo[5,4-d]pyrimidinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for... Agent: Glenmark Pharmaceuticals, S.a.

20120010224 - 6-cyclylmethyl-and 6-alkylmethyl-substituted pyrazolepyrimidines: The invention relates to novel 6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines, process for their preparation and their use for producing medicaments for improving perception, concentration, learning and/or memory.... Agent:

20120010225 - Pharmaceutical composition: The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a... Agent: Kyowa Hakko Kirin Co., Ltd.

20120010226 - Composition for skin external application containing gallocatechin gallate for moisturizing effect on the skin: The present invention relates to a composition for external skin application having a skin-moisturizing effect, which comprises gallocatechin gallate as an active ingredient. More particularly, the composition for external skin application comprises gallocatechin gallate as an active ingredient to activate peroxisome proliferator activated receptor isoform alpha (PPAR-α), to stimulate expression... Agent: Amorepacific Corporation

20120010227 - Formulation for nail and nail bed diseases: The invention relates to a pharmaceutical composition with a content in active ingredient that can be an antimycotic, so that the composition is suitable for the treatment of onychomycoses, in particular severe onychomycoses. The inventive formulation is an ointment-like thermogel at body temperature and an inviscid thermogel at lower temperatures... Agent: Technische Universitat Braunschweig

20120010228 - D2 antagonists, methods of synthesis and methods of use: e

20120010230 - Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling: Provided herein are methods, assays and kits for evaluating a sample, e.g., a sample obtained from a cancer patient, to detect one or more hedgehog biomarkers and/or one or more cilium markers. Thus, the invention can be used, inter alia, as a means to identify patients likely to benefit from... Agent:

20120010229 - Therapeutic regimens for hedgehog-associated cancers: Provided herein are methods, therapeutic regimens, and kits that optimize the benefits of hedgehog inhibition for cancer therapy.... Agent:

20120010231 - Dihydroetorphines and their preparation: The present invention provides a process for the preparation of a compound of formula (VI), or a salt or derivative thereof, wherein R1 and R2 are independently C1-8 alkyl and * represents a stereocentre.... Agent: Euro-celtique S.a.

20120010232 - Compositions for affecting weight loss: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are... Agent: Orexigen Therapeutics, Inc.

20120010233 - Methods and compositions to inhibit edema factor and adenylyl cyclase: Small molecules and their derivatives are described for the treatment and/or prevention of intestinal fluid loss. Also disclosed are methods of using said molecules and their derivatives to treat and/or prevent conditions associated with increased levels of 3′,5′-adenosine monophosphate. Specific compositions of the invention are also novel.... Agent: Mission Pharmacal Co.

20120010234 - Use of vegf-d in the diagnosis of lymphangioleiomyomatosis (lam) disease: Described herein are methods of diagnosing lymphangioleiomyomatosis (LAM) that permits differentiating LAM from another lung disorder. Methods of treatment are also provided.... Agent: Children's Hospital Medical Center

20120010235 - N-substituted pyrrolidines: s

20120010236 - Quinuclidine compounds having quaternary ammonium group, its preparation method and use as blocking agents of acetylcholine:

20120010239 - 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof: The subject invention provides 5-chloro-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide, its salts and uses.... Agent:

20120010237 - Compounds having antiparasitic or anti-infectious activity: e

20120010238 - Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof: The subject invention provides deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, its salts and uses.... Agent:

20120010240 - Cut-point in pten protein expression that accurately identifies tumors and is predictive of drug response to a pan-erbb inhibitor: A cut-point in the quantitative measurement of PTEN protein expression that accurately identifies tumors with two inactivated alleles of the PTEN gene. Patients with a normalized PTEN score of PTEN null will be treated with a pan-ErbB tyrosine kinase inhibitor. A normalized PTEN protein expression score is obtained by comparing... Agent: Wyeth LLC

20120010241 - Hsp90 inhibiting indazole derivatives, compositions containing same and use thereof: The invention relates to novel products having formula (I), wherein: R4 represents H, CH3, CH2CH3, CF3, F, Cl, Br, I; Het represents a heterocycle optionally substituted by one or more R1 or R′1 radicals selected from H, halogen, CF3, nitro, cyano, alkyl, hydroxy, mercapto, amino, alkylamino, dialkylamino, alkoxy, phenylalkoxy, alkylthio,... Agent: Sanofi

20120010242 - Low dose pipamperone in treating mood disorders: The present invention relates to the use of low dose pipamperone and compositions comprising the same for the treatment of mood disorders.... Agent: Alkerstraat 30 A

20120010243 - Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects: The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method... Agent:

20120010244 - Indole derivatives as ikk2 inhibitors: The invention is directed to a certain novel compound which is an inhibitor of kinase activity, in particular IKK2 activity.... Agent: Glaxosmithkline LLC

20120010245 - Transdermal pharmaceutical compositions comprising a serm: The present invention relates to transdermal pharmaceutical compositions such as gels containing a SERM selected from the group consisting of endoxifen, droloxifene, clomifene, raloxifene, tamoxifen, 4-OH tamoxifen, toremifene, danazol and the pharmaceutically acceptable salts thereof, and to methods of making and using the same.... Agent: Besins Healthcare Luxembourg Sarl

20120010246 - Compositions and methods for treating diseases of the nail: Methods and compositions for treating disorders of the nail and nail bed. Such compositions contain a vehicle in which all components of the composition are dissolved, suspended, dispersed, or emulsified, a non-volatile solvent, a wetting agent, and a pharmaceutically active ingredient that is soluble in the non-volatile solvent and/or a... Agent: Dow Pharmaceutical Sciences, Inc.

20120010247 - Bicyclic compound: t

20120010248 - Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof: The present invention provides compounds that function as modulators of mitochondrial aldehyde dehydrogenase-2 (ALDH2) activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. The present invention further provides assays for identifying agonists of ALDH2.... Agent:

20120010250 - Anthranilamide derivatives as pesticides: e

20120010249 - Anthranilic diamide derivatives having cyclic side-chains:

20120010251 - Pest controlling composition: The present invention provides a pest controlling composition comprising, as active ingredients, an amide compound of the formula (I) and a pyrethroid compound; and so on.... Agent:

20120010252 - Fungicidal mixtures of thiophene derivative: wherein W, A, B, D and R5 are disclosed in this specification, and agriculturally suitable salts thereof; and optionally (c) at least one compound selected from the group of compounds acting at the demethylase enzyme of the sterol biosynthesis pathway and agriculturally suitable salts thereof.... Agent:

20120010253 - Fungicidal compositions comprising fluopyram and metrafenone: Fungicidal compositions comprising as active components Fluopyram and Metrafenone in a synergistically effective amount, methods for controlling phytopathogenic harmful fungi using mixtures of Fluopyram and Metrafenone, the use of Fluopyram and Metrafenone for preparing such mixtures, and also compositions and seed comprising such mixtures.... Agent: Basf Se

20120010254 - Compounds and methods for treatment of influenza: The present invention provides in part a compound of Formula (I) or a pharmaceutically-acceptable salt or stereoisomer thereof: where R1 is selected from the group consisting of a substituted triazole group, a guanidine group, a urea group, a thiourea group, an amidine group, and N3; and R2 is selected from... Agent: Simon Fraser University

20120010255 - Compounds and methods for regulating integrins: The application describes small molecules capable of modulating activity of beta2 family of integrins, such as integrin CD11b/CD18 (also known as Mac-1, CR3 and αMβ2). Such compounds may be used in certain embodiments for treating a disease or condition, such as inflammation, immune-related disorders, cancer, ischemia-reperfusion injury, stroke, neointimal thickening... Agent:

20120010256 - Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1: wherein R1, R2, R3, R4, R5, R6, R7, X and Z are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as methods of use of the compounds for treatment of disorders associated with human 11-β-hydroxysteroid dehydrogenase type 1 enzyme and for the preparation of a... Agent: Amgen Inc.

20120010257 - Modulators of cystic fibrosis transmembrane conductance regulator: The present invention relates to modulators of cystic fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating CFTR mediated diseases using such modulators.... Agent: Vertex Pharmaceuticals Incorporated

20120010258 - Additional therapeutic use: The invention relates to the use of an AT1 receptor antagonist or an AT2 receptor modulator, respectively, or a pharmaceutically acceptable salt thereof, for producing a pharmaceutical preparation for the treatment of conditions or diseases associated with the increase of AT1 receptors in the sub-epithelial area or increase of AT2... Agent:

20120010259 - Methods of treating an overweight or obese subject: The invention herein generally relates to methods of treating a subject having an overweight or obese condition, and overweight- or obesity-related conditions. In one embodiment, the invention herein provides a method of treating a subject having an overweight or obese condition involving administering to the subject in need thereof, an... Agent:

20120010260 - Method for treating nervous system disorders and conditions: The present invention is directed to racemic 1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, racemic 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and (+)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and methods of their use for treating certain nervous system disorders and conditions, including, inter alia, vasomotor symptoms (VMS) and chronic pain.... Agent:

20120010261 - Choline and tromethamine salt of licofelone: The present invention relates to the choline and tromethamine salt of Licofelone.... Agent: C-a-i-r Biosciences Gmbh

20120010262 - Crystalline polymorphic forms of an antidiabetic compound: The present invention relates to polymorphic forms of a compound of formula A: This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates,... Agent:

20120010263 - Acetylene derivatives having mglur 5 antagonistic activity: e

20120010264 - Novel medicament for treating cognitive impairment: The present invention provides a medicament for preventing and/or treating cognitive impairment, in particular Alzheimer's dementia, comprising 2-methyl-2-[(4-{(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl}benzyl)oxy]propionic acid or a pharmaceutically acceptable salt or solvate thereof.... Agent: Dainippon Sumitomo Pharma Co., Ltd.

20120010265 - Crystalline form of a 3-phenoxymethylpyrrolidine compound: The invention provides a crystalline hydrochloride salt of (S)-3-[(S)-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases.... Agent:

20120010277 - Avermectin compounds and treatment of dermatological disorders in humans therewith: Compounds of the avermectin family or derivatives thereof, notably latidectin, are formulated into pharmaceutical compositions useful for the treatment of dermatological conditions in humans, in particular rosacea.... Agent: Galderma S.a.

20120010278 - Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections: In certain aspects, the invention relates to methods of treating proliferative cervical disorders (such as cervical cancer and cervical dysplasia) and treating virus infection by administering artemisinin-related compounds. In certain aspects, the invention relates to methods of treating a tumor induced by an oncogenic virus, methods of killing or inhibiting... Agent:

20120010279 - Composition comprising (-)-delta9-trans-tetrahydrocannabinol: A composition comprising a tetrahydrocannabinol compound, a solvent and an acid, wherein the tetrahydrocannabinol compound may be Δ8 tetrahydrocannabinol, (−)-Δ9-trans-tetrahydrocannabinol or a side chain alkyl derivative of either compound, the solvent may be an oil or C1-C4 alcohol (e.g. sesame oil or ethanol), and the acid may be an organic... Agent: Johnson Mathey Public Limited Company

20120010280 - Ophthalmic compositions based on polyunsaturated omega-3 and omega-6 fatty acids: The invention concerns topical compositions for the prevention and treatment of ocular pathologies, in particular inflammatory keratites and conjunctivites and dry eye syndrome, containing as active ingredients polyunsaturated fatty acids of the types omega-3 and omega-6, and specifically EPA (eicosapentaenoic acid), DHA (docosahexaenoic acid) and GLA (γ-linolenic acid), mixed with... Agent: Trb Chemedica International S.a.

20120010281 - Antimicrobial and antitubercular compounds: Infections caused by Mycobacterium tuberculosis kill more than 1.8 million people each year. While the persistence of this pathogenic bacterial species and the emergence of multidrug resistant strains have created an urgent need for new TB therapies, a new TB-specific drug has not been developed in over 40 years. The... Agent: The Trustees Of Princeton University

20120010282 - Tautomycetin and tautomycetin analog biosynthesis: The present invention relates to the biosynthetic gene cluster for tautomycetin (TTN) produces tautomycetin. Also provided are engineered micro-organisms for the production of TTN and analogs thereof, as well as methods of screening for compounds for activity.... Agent: Wisconsin Alumni Research Foundation

20120010283 - Modulation of anxiety through blockade of anandamide hydrolysis: are provided wherein X is NH, CH2, O, or S; Q is O or S; Z is O or N; R is an aromatic moiety selected from the group consisting of substituted or unsubstituted aryl; substituted or unsubstituted biphenylyl, substituted or unsubstituted naphthyl, and substituted or unsubstituted phenyl; substituted or... Agent: Universita Degli Studi Di Urbino

20120010284 - Controlled release of biologically active compounds from multi-armed oligomers: The present invention relates to the discovery of biodegradable multi-armed oligomers wherein the end groups of these oligomers have been functionalized with biologically active molecules. The resultant multi-armed oligomers end-functionalized with biologically active molecules have a controllable degradation profile. The hydrolytic degradation of oligomers of the present invention releases the... Agent: Bezwada Biomedical, LLC

20120010285 - Agent for promoting energy consumption: An agent for promoting energy consumption, an agent for promoting fat burning, an agent for promoting carbohydrate burning, an agent for improving an effect of exercise, an agent for improving motor functions, an agent for inhibiting acetyl-CoA carboxylase 2, and an agent for inhibiting pyruvate dehydrogenase kinase 4 containing chlorogenic... Agent: Kao Corporation

20120010286 - Prevention of neutrophil recruitment: Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.... Agent: The Brigham And Women's Hospital, Inc.

20120010287 - N, n -dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same: The present invention relates to N,N-dimethyl imidodicarbonimidic diamide acetate, a method of preparing the same and a pharmaceutical composition comprising the same, and more particularly, to N,N-dimethyl imidodicarbonimidic diamide acetate which is a crystalline acid addition salt prepared by reacting N,N-dimethyl imidodicarbonimidic diamide with acetic acid, and which is very... Agent: Hannal Biopharma Co., Ltd.

20120010288 - Method for protecting a retinal neuronal cell: A method of protecting a retinal neuronal cell by administering an effective amount of a prostaglandin F2α derivative to a patient. A method of preventing or treating an eye disease associated with retinal neuronal cell damage by administering a therapeutically effective amount of a prostaglandin F2α derivative to a patient.... Agent: Asahi Glass Company, Limited

20120010289 - Method for placental exfoliation using oxo-arachidonic acid or the like: A composition for placental exfoliation and a method for placental exfoliation. The composition for placental exfoliation contains an arachidonic acid derivative or the like, and the method for placental exfoliation comprises the step of administering an arachidonic acid derivative or the like to a mammal after the fetal delivery.... Agent: Inc Admin Agcy Natl Agric & Food Res. Organization

20120010290 - Methods of treating an overweight or obese subject: The invention herein generally relates to methods of treating a subject having an overweight or obese condition, and overweight- or obesity-related conditions. In one embodiment, the invention herein provides a method of treating a subject having overweight or obese condition involving administering to the subject in need thereof, an amount... Agent:

20120010291 - Creatine beta-alaninate: a novel salt for increasing athletic performance: Disclosed are creatine β-alaninate, compositions and formulations containing same, and methods of use therefor.... Agent:

20120010293 - Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders: The present invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active ingredients, for the treatment of conditions, such as mood disorders, sleep disorders, or attention deficit disorders. In certain embodiments, the compositions useful in the methods of the invention comprise droxidopa and a... Agent: Chelsea Therapeutics, Inc.

20120010292 - Modification i of 4-(phenyl)ethyl]-amino}methyl)benzoic acid: The invention relates to novel forms of 4-({(4-carboxybutyl)[2-(2-{[4-(2-phenyl-ethyl)benzyl]oxy}phenyl)ethyl]amino}methyl)benzoic acid, in particular to the modification I, to processes for their preparation, to medicaments comprising them and to their use for fighting diseases.... Agent: Bayer Schering Pharma Aktiengesellschaft

20120010294 - Compositions and methods for the inhibition of muscle contraction: Compositions and methods for the inhibition of muscle contraction are disclosed. In one aspect, the present application discloses pharmaceutical compositions comprising analgesic agents for the inhibition of muscle contraction. In another aspect, the application discloses methods for the prophylactic intervention against premature pain associated with the filling of the urinary... Agent:

20120010295 - Synergistic combinations comprising a renin inhibitor for cardiovascular diseases: m

20120010296 - Treating various disorders with catechol-o-methyl-transferase inhibitors: The invention provides methods for treating disorders in patients with catechol-o-methyl-transferase inhibitors, such as impulse control disorders and cognitive disorders, such as attention deficit hyperactivity disorder. The invention also provides methods for treating patients with obsessive compulsive disorders and substance addictions with catechol-o-methyl-transferase inhibitors.... Agent:

20120010297 - Curcuminoids and its metabolites for the application in allergic ocular/nasal conditions: A pharmaceutical composition for nasal administration comprising: a nanoemulsified curcumin component; a liquid medium for the curcumin component; and a pharmaceutically acceptable excipient. The curcumin component is a natural curcuminoid, a synthetic curcuminoid, a metabolite of a natural or synthetic curcuminoid, or a mixture thereof. The excipient is effective in... Agent: Laila Pharmaceuticals Pvt. Ltd

20120010298 - Method for synthesizing (e)-anethol and related compounds by cross coupling reaction of potassium alllyltrifluroborate and 4-bromoanisole and aryl halides: Methods of producing substituted and non-substituted beta-methyl styrene by a cross-coupling reaction are provided. The disclosure also provides for methods of preparing (E)-Anethol and related compounds by a cross coupling reaction of potassium allyltrifluoroborate and 4-bromoanisole and aryl halides. Compounds, compositions, and methods of treating disorders utilizing beta-methyl styrene are... Agent:

20120010299 - Non-prescription medicine, vital fluid, and/or nutritional supplement: The present invention is directed toward a method of administering an oral solution containing one or more active ingredients, preferably formulations for non-prescription medicines, vital fluids, and/or nutritional supplements, optimally dosed based upon a patient's weight. The method includes providing an oral solution having an effective amount of one or... Agent:

20120010300 - Effect pigments based on coated glass flakes: The present invention relates to effect pigments based on thin glass flakes and to a method for the production of such pigments. The resulting pigment can be used in any application for which pearlescent pigments have been heretofore used such as, for example, in plastics, paints, inks, cosmetic formulations, coatings... Agent:

20120010301 - Organoleptic compounds: e

20120010302 - New types of polyester-modified organopolysiloxanes: The invention relates to new types of polyester-polysiloxane block copolymers, to processes for their preparation and to their use.... Agent: Evonik Goldschmidt Gmbh

20120010303 - Waxes derived from metathesized natural oils and amines and methods of making: Wax compositions derived from metathesized natural oils and amines and methods of making wax compositions from metathesized natural oils and amines are provided. The wax compositions comprise amidated metathesized natural oils formed from a metathesized natural oil and at least one amine. The methods comprise providing an amine and providing... Agent:

  
01/05/2012 > 172 patent applications in 127 patent subcategories. recently filed with US Patent Office

20120004157 - Hydroxyproline compositions and uses thereof: The invention concerns novel use for Hydroxyproline in a pharmaceutical or dietary food or feed compositions for promoting growth e.g. of fish and/or for treating, ameliorating, or curing certain disorders including osteoporosis, psoriasis, enteritis and gingivitis.... Agent: Bergen Teknologioverforing As

20120004158 - Quaternised ammonium cyclodextrin compounds: e

20120004159 - Polypeptides having antimicrobial activity and polynucleotides encoding same: The present invention relates to isolated polypeptides having antimicrobial activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.... Agent: Novozymes A/s

20120004160 - Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation: The present invention relates to agents, and methods for identifying compounds, which agents and compounds result in the inhibition of the activation of macrophages. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by activation of macrophages including infections, allograft... Agent: Bio-focus Dpi B.v.

20120004161 - Homogenous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc

20120004162 - Methods of treating an overweight or obese subject: The disclosure herein generally relates to methods of treating an over eight or obese condition, and overweight- or obesity-related conditions. In one embodiment, the disclosure provides a method of treating an overweight or obese condition involving administering to the subject in need thereof, an amount of a pharmaceutical composition including... Agent:

20120004163 - Nutritional composition for infants: A nutritional composition for infants comprises a protein source, a lipid source and a carbohydrate source wherein the lipid source includes at least 16 wt % linoleic acid and at least 2 wt % α-linolenic acid expressed as a percentage of total fatty acid content in each case and in... Agent: Nestec S.a.

20120004164 - Organic compounds: The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.... Agent: Novartis Ag

20120004167 - (2-aryloxyacetylamino) phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments: e

20120004166 - Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament:

20120004165 - Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments:

20120004168 - Exendins and exendin agonist analogs to regulate gastrointestinal motility: Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired post-prandial blood glucose levels are disclosed which comprise administration of... Agent: Amylin Pharmaceuticals, Inc.

20120004169 - Materials and methods for treatment of cancer and identification of anti-cancer compounds: The subject invention pertains to the treatment of tumors and cancerous tissues and the prevention of tumorigenesis and malignant transformation through the modulation of JAK/STAT3 intracellular signaling. The subject invention concerns pharmaceutical compositions containing cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof. Another aspect of the invention concerns... Agent: University Of South Florida

20120004170 - Formulation comprising bioactive agents and method of using same: Disclosed are methods of making bioactive BMP-2 microparticles and methods of using the microparticles.... Agent: Wyeth

20120004171 - Novel therapies for chronic renal failure: The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain proteins of, or based upon, the osteogenic... Agent: Stryker Corporation

20120004173 - Methods and compositions for treating skin aging and scars: It is to provide a method for treating skin aging, or a method for treating skin scar that can exert a sufficient effect. A composition for treating skin aging comprising bFGF for treating aging of the skin that is administered intradermally or subcutaneously, or a composition for treating skin scar... Agent: Labo Juversa Co., Ltd.

20120004172 - Screening method of anti-lung or esophageal cancer compounds: Disclosed herein is a method for determining a kinase activity of ERK for CDCA5 and methods of screening for modulators of this kinase activity. Also disclosed are methods and pharmaceutical compositions for preventing and/or treating lung cancer or esophageal cancer that use or include such modulators.... Agent: Oncotherapy Science, Inc.

20120004174 - Gh secretagogues and uses thereof: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime... Agent: Theratechnologies Inc.

20120004175 - Inhibitors of nf-kb activity: The present invention provides a method for inhibiting NF-κB activity in a subject, the method comprising providing an agent capable of inducing expression of annexin 1, whereby said agent induces expression of annexin 1 and whereby said induced expression of annexin 1 inhibits NF-κB activity. Also provided are annexin 1... Agent: The Research Foundation Of State University Of New York

20120004176 - Liquid composition of factor vii polypeptides: A liquid aqueous composition comprising (i) a factor VII polypeptide, (ii) an agent suitable for keeping pH in the range of from about 4.0 to about 8.0; (iii) an agent selected from the list of: a calcium salt, a magnesium salt, or a mixture thereof; wherein the concentration of (iii)... Agent: Novo Nordisk A/s

20120004177 - Compositions and methods of delivery of pharmacological agents: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of... Agent:

20120004178 - Biglycan mutants and related therapeutics and methods of use: The present disclosure provides compositions and methods for treating diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting... Agent:

20120004179 - Means and methods for manufacturing highly pure neurotoxin: The present invention relates to an antibody which specifically binds to unprocessed and/or partially processed neurotoxin polypeptide or an antibody which specifically binds an epitope consisting of a peptide having an amino acid sequence as shown in any one of SEQ ID NOs: 1 to 16 and to methods for... Agent: Merz Pharma Gmbh & Co. Kgaa

20120004180 - Method of producing a novel opioid peptide: The use of opioid peptides of a novel structure is claimed which, in addition to a pharmacophore, additionally contain structural elements reactive with tachykinin receptors. Due to the synergistic reactivity of the opioid with an additional element, an increased analgesic activity is obtained facilitating protracted effective use due to decreased... Agent:

20120004181 - Targeted delivery system: The present invention relates a targeted delivery system for siRNA or antisense technology. In one embodiment, the invention provides for a method of treating cancer by administering a therapeutically effective dosage of HerPBK10 combined with siRNA, resulting in the inhibition of Her2 expression and cell death. In another embodiment, a... Agent: Cedars-sinai Medical Center

20120004182 - Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells: The present invention relates to methods for inducing and/or enhancing apoptosis in pathogenic cells. In particular, the present invention relates to the use of GnRH II antagonists in combination with at least one further compound selected from the group of selective estrogen receptor modulators (SERM), Aromatase inhibitors, and glycolysis inhibitors... Agent:

20120004184 - Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Nu-clear factor (erythroid-derived 2)-like 2 (NRF2), in particular, by targeting natural antisense polynucleotides of Nuclear factor (erythroid-derived 2)-like 2 (NRF2). The invention also relates to the identification of these antisense oligonucleotides and their use in... Agent:

20120004183 - Unnatural reactive amino acid genetic code additions: This invention provides compositions and methods for producing translational components that expand the number of genetically encoded amino acids in eukaryotic cells. The components include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, pairs of tRNAs/synthetases and unnatural amino acids. Proteins and methods of producing proteins with unnatural amino acids in eukaryotic cells... Agent: The Scripps Research Institute

20120004186 - Platelet aggregation inhibitor composition: i

20120004185 - Polypeptide structural motifs associated with cell signaling activity: Isolated polypeptides comprising or consisting essentially of specific structural motifs (e.g., three β-sheets and two α-helices) are provided, wherein the polypeptides exhibit at least one cell signaling and/or other non-canonical activity of biological relevance. Also provided are polynucleotides encoding such polypeptides, binding agents that bind such polypeptides, analogs, variants and... Agent: Atyr Pharma, Inc.

20120004187 - Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament: o

20120004188 - Use of ranolazine for treating pulmonary hypertension: This disclosure relates generally to treating patients having pulmonary hypertension such as pulmonary arterial hypertension (PAH), or symptoms associated therewith, by administering a therapeutically effective amount of ranolazine or a salt or salts thereof to the patient.... Agent: Gilead Sciences, Inc.

20120004189 - Compositions and products containing s-equol, and methods for their making: A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in... Agent: Children's Hospital Medical Center

20120004190 - Heterobifunctional pan-selectin inhibitors: Compounds and methods are provided for modulating in vitro and in vivo processes mediated by selectin binding. More specifically, selectin modulators and their use are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics alone or linked to a member of a... Agent: Glycomimetics, Inc.

20120004279 - Compositions and methods for modulating activity of capped small rnas: Compositions and methods for modulating transcription by RNA polymerases are described.... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20120004278 - Linc rnas in cancer diagnosis and treatment: Long non-coding RNAs (lincRNAs), a relatively recently recognized class of widely transcribed genes, are thought to affect chromatin state and epigenetic regulation, but their mechanisms of action and potential roles in human disease are poorly understood. The present invention shows that long non-coding RNAs in the human HOX loci are... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20120004276 - Rna antagonist compounds for the inhibition of expression of mitochondrial glycerol-3 phosphate acyltransferase 1 (mtgpat1): The present invention relates to oligomer compounds (oligomers), which target mtGPAT1mRNA in a cell, leading to reduced expression of mtGPAT1. Reduction of mtGPAT1 expression is beneficial for the treatment of certain medical disorders, such as overweight, obesity, fatty liver, hepatosteatosis, non alcoholic fatty liver disease (NAFLD), non alcoholic steatohepatitis (NASH),... Agent:

20120004280 - Rna interference mediated inhibition of the high affinity 1 ge receptor alpha chain (fc epsilon r1 alpha) gene expression using short interfering nucleic acid (sina): The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of FCεR1α gene expression and/or or activity, and/or modulate a FCεR1α gene expression pathway. Specifically, the invention relates to doublestranded nucleic acid molecules including small... Agent: Merck Sharp & Dohme Corp.

20120004282 - Rna interference mediated inhibition of the intercellular adhesion molecule 1 (icam-1) gene expression using short interfering nucleic acid (sina): The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of ICAM-1 gene expression and/or activity, and/or modulate a ICAM-1 gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic... Agent: Merck Sharp & Dohme Corp,

20120004281 - Rna interference mediated inhibition of the nerve growth factor beta chain (ngfb) gene expression using short interfering nucleic acid (sina): The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of NGFβ gene expression and/or activity, and/or modulate a NGFβ gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic... Agent: Merck Sharp & Dohme Corp

20120004277 - Vector(s) containing an inducible gene encoding a cdk4/cdk6 inhibitor useful for treating neurodegenerative disorders or diseases associated with an unscheduled activation of the cell cycle: Described are vectors containing (a) a gene encoding (i) a CDK4/CDK6 inhibitor, preferably p16INK4a, or (ii) an RNA interfering with CDK4 and/or CDK6 expression and/or activity, under the control of an inducible promoter and (b) a gene encoding a transactivator protein for said promoter useful for treating neurodegenerative disorders. These... Agent:

20120004289 - Annexin a11 and associated genes as biomarkers for cancer: The instant invention provides methods and compositions for the diagnosis and treatment of cancer. The invention also provides method and compositions for determining if a subject is, or is at risk of becoming, chemoresistant.... Agent: The Johns Hopkins University

20120004288 - Compounds for the modulation of beta-catenin expression: The invention relates to oligomer compounds (oligomers), which target beta-catening mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating... Agent: Enzon Pharmaceuticals, Inc.

20120004285 - Erbb-3 (her3)-selective combination therapy: The invention relates to pharmaceutical compositions for and methods of treatment with HER3-targeted combination therapy. The invention relates to pharmaceutical compositions comprising an oligomer which targets HER3 (and optionally one or more of HER2 and EGFR) mRNA in a cell, leading to reduced expression of HER3 and optionally HER2 and/or... Agent: Enzon Pharmaceuticals, Inc.

20120004286 - Long-acting veterinary polypeptides and methods of producing and administering same: A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.... Agent:

20120004283 - Novel shrna gene therapy for treatment of ischemic heart disease: Short hairpin RNA (shRNA) interference therapy targeting hypoxia inducible factor—lot (HIF-1 α) prolyl-4-hydroxylase protein (HIF-PHD2) is used for treatment of myocardial ischemia. This treatment can be followed noninvasively by molecular imaging. Provided are compositions comprising novel vectors encoding shRNA targeting the HIF-1α and asparaginyl hydroxylase genes. The vectors encoding shRNA... Agent: The Board Of Trustees Of The Leland Stanford Junio

20120004284 - Pdk inhibitor compounds and methods of use thereof: The invention relates to methods of treating or preventing acquired or congenital mitochondrial diseases or disorders, including treating cell proliferation related disorders or diseases, such as cancer. The invention further relates to pharmaceutical compositions for treating such disorders or diseases.... Agent: University Of Florida Research Foundation

20120004287 - Therapeutic agent comprising vasohibin: A therapeutic agent containing Vasohibin for diabetic nephropathy, and a therapeutic agent containing Vasohibin for peritoneal sclerosis. Since the therapeutic agent containing Vasohibin of the present invention is a substance in which Vasohibin inhibits angiogenesis in an autocrine manner, the therapeutic agent is effective for inhibiting the progression of diabetic... Agent:

20120004290 - Treating chronic fatigue syndrome and prolonged qt interval: Chronic fatigue syndrome and prolonged QT interval are treated using one or more different double-stranded ribonucleic acids (dsRNA).... Agent:

20120004191 - Combinational compositions and methods for treatment of cancer: The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or a pyrroloquinolinyl-pyrrolidine-2,5-dione compound in combination with a therapeutically effective amount of a second anti-proliferative agent.... Agent: Arqule, Inc.

20120004193 - Process for production of orally ingestible composition containing arabinofuranosyl vitexin, and use of the composition: A method for producing an orally ingestible composition containing an arabinofuranosyl vitexin and/or a hydrolysate thereof by using Basella alba as a raw material. The product of such method has a sedative effect and a sleep-inducing effect.... Agent: Fuji Sangyo Co., Ltd.

20120004192 - Use of lactulose in the treatment of autism: A treatment for autism in which an effective amount of lactulose is administered in order to bind excess ammonia in the gastrointestinal tract, the bloodstream, and the nervous system in order to prevent or reverse ammonia poisoning caused by the administration of certain antibiotics. Lactulose molecules in the colon are... Agent: Curemark LLC

20120004194 - Aldehyde-functionalized polysaccharides: Novel aldehyde-functionalized polysaccharide compositions are described that are more stable in aqueous solution than oxidized polysaccharides or other types of polysaccharides containing pendant aldehyde groups. The aldehyde-functionalized polysaccharides may be reacted with various amine-containing polymers to form hydrogel tissue adhesives and sealants that may be useful for medical applications such... Agent: E. I. Du Pont Nemours And Company

20120004195 - Cyclodextrin-based polymers for therapeutic delivery: Methods and compositions relating to CDP-proteasome inhibitor conjugates are described herein.... Agent:

20120004196 - Anti-viral compounds: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.... Agent: Abbott Labaoratories

20120004197 - Prophylactic and/or therapeutic agent for anemia comprising tetrahydroquinoline compound as active ingredient: Disclosed is a compound which has a low molecular weight and has an activity of enhancing the production of EPO and/or an activity of enhancing the production of hemoglobin. Specifically disclosed is and EPO production enhancer and/or a hemoglobin production enhancer comprising a 1-acyl-4-(substituted oxy, substituted amino, or substituted thio)-1,2,3,4-tetrahydroquinoline... Agent: Kowa Company, Ltd.

20120004198 - Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators: Provided herein are non-peptide GLP-1 receptor modulator compounds, for example, of Formula I, pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of a metabolic disorder.... Agent: Argusina Inc.

20120004199 - Scaffolds: The invention relates to a wound dressing comprising an electrospun scaffold. The scaffold comprises a biodegradable polymer or co-polymer and a nonsteroidal anti-inflammatory drug.... Agent:

20120004200 - Topical pharmaceutical composition containing a water-sensitive active principle: A topical pharmaceutical composition including, as a pharmaceutical active agent, a water-sensitive compound in a solubilised form in a physiologically acceptable medium is described. A method for preparing such a composition, and uses thereof in dermatology are also described.... Agent: Galderma S.a.

20120004202 - Medicaments for the treatment or prevention of fibrotic diseases: t

20120004201 - Phosphodiestarase inhibitors: The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4/PDE type 7 inhibitors. Compounds disclosed herein can be useful in the treatment, prevention, inhibition or suppression of CNS diseases, for example, multiple sclerosis; various pathological conditions such as diseases affecting the immune... Agent:

20120004203 - Triazolo and tetrazolo pyrimidine derivatives as hne inhibitors for treating copd: The present invention relates to novel heterocyclically fused diaryldihydropyrimidine derivatives, to processes for their preparation, to their use alone or in combination for the treatment and/or prevention of diseases and also to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or... Agent: Bayer Schering Pharma Aktiengesellschaft

20120004204 - Methods for treating sexual dysfunction while decreasing cardiovascular risk: Methods for treating female sexual dysfunction are provided. In particular, methods for treating a woman having HSDD by administering to the woman a therapeutically effective amount of an androgen, whereby the therapeutically effective amount of the androgen is administered in a manner that results in a reduction in expected number... Agent: Biosante Pharmaceuticals, Inc.

20120004205 - Il-13 induced gene signature for eosinophilic esophagitis: The present invention concerns methods useful in diagnosing, identifying and monitoring the progression of eosinophilic esophagitis through measurements of gene products induced by IL-13.... Agent: Cincinnati Children's Hospital Medical Center

20120004206 - Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other... Agent:

20120004207 - Therapeutic uses of derivatives of piperidinyl-and piperidinyl-alkyl carbamates: e

20120004208 - Benzoyl-piperidine derivatives as dual modulators of the 5-ht2a and d3 receptors:

20120004209 - 11-beta-hydroxysteroid dehydrogenase type 1 active compounds: A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxy-steroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment... Agent: High Point Pharmaceuticals, LLC

20120004210 - Substituted quinazoline compounds: The invention is directed to certain novel compounds, methods for producing them and methods for treating or ameliorating a kinase-mediated disorder. More particularly, this invention is directed to substituted quinazoline compounds useful as selective kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase-mediated disorder,... Agent: Fovea Pharmaceuticals Sa

20120004211 - 1,2,4-triazole derivatives as sigma receptor inhibitors: e

20120004213 - Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase: The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.... Agent: Forest Laboratories Holdings Limited

20120004212 - Organic compounds: e

20120004214 - N-oxides of 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives useful as nicotinic acetylcholine receptor ligands: This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of... Agent: Neurosearch A/s

20120004215 - N-oxides of diazabicyclononyl pyrimidine derivatives and their medical use: This invention relates to novel N-oxides of certain diazabicyclononyl pyrimidine derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the... Agent: Neurosearch A/s

20120004216 - Modulators of atp-binding cassette transporters: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including CF Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.... Agent: Vertex Pharmaceuticals Incorporated

20120004217 - Therapeutic agents useful for treating pain: wherein Ar1, A, R3, x, and m are as disclosed herein and Ar2 is a benzothiazolyl, benzooxazolyl, or benzoimidazolyl group or a pharmaceutically acceptable salt thereof (a “Benzoazolylpiperazine Compound”), compositions comprising a Benzoazolylpiperazine Compound, and methods for treating or preventing pain, UI, an ulcer, IBD, IBS, an addictive disorder, Parkinson's... Agent: Purdue Pharma L.p.

20120004218 - Novel tetrahydro-quinoline derivatives: or a pharmaceutically acceptable salt or ester thereof, wherein A1 to A3 and R1 to R10 have the significance given in claim 1, can be used as a medicament. These compounds are useful in the treatment or prophylaxis of diseases that are related to AMPK regulation, such as obesity, dyslipidemia,... Agent:

20120004219 - Method of inhibition of respiratory depression using positive allosteric ampa receptor modulators: The invention is directed to a method for alleviating respiratory depression in a subject as a result of disease of pharmacological agents such as opiates, opioids or barbiturates. The invention also discloses pharmaceutical compositions for use with the method, the composition containing in combination, an analgesic, anaesthetic, or a sedative... Agent: The Governors Of The University Of Alberta

20120004220 - Selective androgen receptor modulators (sarms) and uses thereof: Provided herein are compounds of formulae I to II that bind to androgen receptors and/or modulate activity of androgen receptors; and to methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.... Agent:

20120004221 - Antibacterial compositions: wherein: m is 0 or 1; Q is hydrogen or cyclopropyl; Alk is an optionally substituted, divalent C1-C6 alkylene, alkenylene or alkynylene radical which may contain an ether (—O—), thioether (—S—) or amino (—NR)— link, wherein R is hydrogen, —CN or C1-C3 alkyl; X is —C(═O)NR6—, —S(O)NR6—, —C(═O)O— or —S(═O)O—... Agent: Biota Europe Limited

20120004222 - Cb2 receptor ligands for the treatment of pain: e

20120004223 - Compounds, compositions and methods for reducing lipid levels: The present technology relates to compounds of Formulas (V) and (VI) and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor... Agent:

20120004224 - Triheterocyclic compounds and compositions thereof: The present invention relates to novel Triheterocyclic Compounds, compositions comprising a Triheterocyclic Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a Triheterocyclic Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or... Agent: Gemin X Pharmaceuticals Canada Inc. (formerly Gemin X Biotechnologies Inc.)

20120004228 - Bis aromatic compounds for use as ltc4 synthase inhibitors: wherein Y, ring A, Da, Db, D2, D3, L1, Y1, L2, Y2, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and particularly in the treatment... Agent: Biolipox Ab

20120004225 - Bumetanide, furosemide, piretanide, azosemide, and torsemide analogs, compositions and methods of use: The present invention provides bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and methods for their use. All of these analogs are particularly useful for the treatment and/or prophylaxis of... Agent: Neurotherapeutics Pharma, Inc.

20120004227 - Cyclohexane derivative having npy y5 receptor antagonism: wherein A is substituted or unsubstituted aryl or heterocyclyl; a combination of X and Y is a combination selected from (X, Y)═(C(═O)N(R1), C(═O)N(R2)), (C(═O)N(R1), imidazole-1,3-diyl), (N(R1), C(═O)N(R2)), (O, C(═O)N(R2)), (C(R3)(R4), N(R2)) or (a single bond, C(═O)N(R2)); R1, R2 and R3 are independently hydrogen or substituted or unsubstituted alkyl; R5 is... Agent: Shionogi & Co., Ltd.

20120004226 - Modulators of muscarinic receptors: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.... Agent: Vertex Pharmaceuticals Incorporated

20120004230 - Imidazole derivatives: e

20120004229 - Substituted diketopiperazines and their use as oxytocin antagonists:

20120004231 - Substituted pyridazine derivatives: The present invention is directed to compounds having histamine H3 antagonist activity, as well as methods of their use and preparation.... Agent: Cephalon, Inc.

20120004232 - 2-amino-bicyclo(3.1.0) hexane-2, 6-dicarboxylic ester derivative: [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a... Agent: Taisho Pharmaceutical Co., Ltd.

20120004233 - Tricyclic compounds as antagonists of prostaglandin d2 receptors: Described herein are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.... Agent: Amira Pharmaceuticals, Inc

20120004235 - Methods to treat cancer: The invention provides methods and pharmaceutical compositions for treating certain cancers with compounds of formula (I) wherein A, B, W, Y, Z, and R1 have any of the meanings defined in the specification and their pharmaceutically acceptable salts and prodrugs.... Agent: Old Queens Building, Somerset And George Streets

20120004234 - Phthalazine-containing antidiabetic compounds: This invention provides for certain phthalazine-containing compounds of the formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof, wherein G is an optionally substituted N—N containing heteroaryl group and the variables are defined herein; the inventive compounds are agonists of the G-protein coupled receptor 40 (GPR40, also known... Agent: Schering Corporation

20120004237 - Salt of cd 80 antagonist: Choline salt of the CD80 antagonist compound 4-(6-fluoro-3-oxo-1,3-dihydro-pyrazolo[4,3-c]cinnolin-2-yl)-N-(2,2-difluoro-ethyl)-benzamide.... Agent: Medigene Ag

20120004236 - Substituted triazolo-pyridazine derivatives: This invention relates to novel substituted triazolo-pyridazines, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an α1-GABA-A receptor antagonist and/or a... Agent: Concert Pharmaceuticals Inc.

20120004238 - L-methylfolate treatment for psychiatric or neurologic disorders: Provided herein are methods of treating neuropsychiatric disorders or improving the symptoms associated therewith administering a medical food, such as L-methylfolate, to a subject having the disorder. The neuropsychiatric disorder may be an autism spectrum disorder or attention deficit disorder with or without hyperactivity (ADD/ADHD). The L-methylfolate may be administered... Agent:

20120004239 - process for preparing quinoxaline derivatives: The present invention provides an improved process for preparing a compound of formula (IIIA), an intermediate of the synthesis of varenicline. Also, the present invention provides an improved process for preparing varenicline, or a pharmaceutically acceptable salt or solvate thereof. Furthermore, the present invention provides a process for decolorizing varenicline,... Agent: Medichem, S.a.

20120004240 - Inhibitors of akt activity: The instant invention provides for substituted fused naphthyridine derivatives that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient... Agent:

20120004241 - Succinate salt of (2r)-methyl-1-piperazine: e

20120004242 - Oligomer-diarylpiperazine conjugates: The invention relates to (among other things) oligomer-diarylpiperazine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated diarylpiperazine compounds.... Agent: Nektar Therapeutics

20120004243 - Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors: The invention concerns a compound of the Formula (I), wherein Qa is heteroaryl and is substituted with halogeno; R1 and R2 are hydrogen; and Qb is phenyl or heteroaryl, and Qb may optionally bear 1 or 2 substituents selected from hydroxy, halogeno and (1-6C)alkyl, or a pharmaceutically-acceptable salt thereof; processes... Agent: Astrazeneca Ab

20120004244 - Bis aromatic compounds for use as ltc4 synthase inhibitors: wherein E1, E2a, E2b, E2c, E4, D1, D2, D3, L1, Y1, L2 and Y2 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and particularly in the treatment of... Agent: Biolipox Ab

20120004245 - Compounds for the treatment of posterior segment disorders and diseases: The use of certain urea compounds, for the treatment of retinal disorders associated with pathologic ocular angiogenesis and/or neovascularization is disclosed.... Agent: Alcon Research, Ltd.

20120004246 - Purinyl derivatives and their use as potassium channel modulators: This invention relates to novel purinyl derivatives and their use as potassium channel modulating agents. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels.... Agent: Neurosearch A/s

20120004247 - Organic compounds: i

20120004248 - Methods of using a methylxanthine compound: The invention relates to compositions and methods for treating various diseases or medical conditions by administering a methylxanthine compound. Specifically, the invention relates to compositions and methods for treating cytochrome oxidase (CcOX) mediated diseases or medical conditions by administering compositions comprising a methyl xanthine compound.... Agent:

20120004249 - The polymorph forms of 4-anilinoquinazoline derivatives, the preparation methods and uses thereof: The present invention relates to polymorphic forms of N-{4-[3-chloro-4-(3-fluoro-benzyloxy)phenylamino]-quinazolin-6-yl}-acrylamide p-toluenesulfonate with the characteristic X-ray powder diffraction data as stated in the description, preparation methods thereof, pharmaceutical compositions comprising the same and the use thereof.... Agent:

20120004250 - Pyrimidine classical cannabinoid compounds and related methods of use: e

20120004251 - Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy: This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is... Agent: Gw Pharma Limited

20120004252 - New ccr2 receptor antagonists and uses thereof: The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.... Agent: Boehringer Ingelheim International Gmbh

20120004253 - Novel fused pyrrolocarbazoles: The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.... Agent: Cephalon, Inc.

20120004254 - G protein-coupled receptor antagonist and its use for preventing and treating alzheimer's disease: The invention discloses methods for screening a reagent for treating or preventing Alzheimer's disease or related neurological pathology. A method according to the invention includes the steps of: (a) activating a receptor and determining a first extent of endocytosis of the receptor, wherein the receptor is a G-protein coupled receptor... Agent: Shanghai Institutes For Biological Sciences, Chinese Academy Of Sciences

20120004255 - Dual phase drug release system: e

20120004256 - Parenteral formulation of clopidogrel: Described herein are ways to solubilize clopidogrel for parenteral administration containing clopidogrel and a diluent NNDMA (N,N-dimethylacetamide); useful in the prevention of platelet aggregation in acute coronary syndrome, acute myocardial infarction or to prevent platelet facilitated thrombosis following coronary angioplasty and/or coronary stenting.... Agent: Academic Pharmaceuticals Incorporated

20120004257 - Novel compounds: The present applications discloses novel 8-aza-bicyclo[3.2.1]oct-3-yloxy)chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors. In other aspects the applications discloses the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent:

20120004258 - Quinuclidine carbonate salts and medicinal composition thereof: Quinuclidine carbonate derivatives act as muscarinic receptor antagonists and are effective for the prevention and/or treatment of a broncho-obstructive or inflammatory diseases.... Agent: Chiesi Farmaceutici S.p.a.

20120004260 - Inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds and methods of treatment thereof: The present invention relates to a method of treating a fatty acid synthesis related disease comprising administering to a patient in need thereof an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis, wherein the fatty acid synthesis related disease is obesity, diabetes, or cardiovascular... Agent: Bipar Sciences, Inc.

20120004259 - Method of treatment or prophylaxis: The present invention is directed to methods and agents that are useful in the prevention and amelioration of signs and symptoms associated with neuropathic conditions. More particularly, the present invention discloses the use of angiotensin II receptor 2 (AT2 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of... Agent: Spinifex Pharmaceuticals, Pty Ltd

20120004261 - Mif modulators: The invention provides novel heterocyclic compounds, pharmaceutical compositions and methods of treatment that modulate levels of MIF expression and treat disorders associated with high or low levels of MIF expression.... Agent: Yale University

20120004262 - Phenylcyclopropylamine derivatives and their medical use: The present invention relates to phenylcyclopropylamine derivatives. In particular, pharmaceutical compositions comprising phenylcyclopropylamine derivatives are provided. The compounds of this invention can, inter alia, be used for the treatment and the prevention of cancer as well as neurodegenerative diseases or disorders.... Agent:

20120004263 - Compounds for the treatment of pathologies associated with aging and degenerative disorders: The present invention relates to methods of inhibiting one or more signs of aging and/or degenerative disorder in a subject in need of such treatment, which comprise administering, to the subject, an effective amount of one or more of the compounds as set forth herein. “Inhibiting a sign of aging... Agent: University Of Pittsburgh - Of The Commonwealth System Of Higher Education

20120004264 - 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them: 4-(trifluoromethanesulfonyloxyphenyl)propionic acid derivatives and pharmaceutical composition containing such compounds are useful in inhibiting the chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. Notably, these... Agent: Domp&#xe9 Pha.r.ma S.p.a.

20120004265 - Ophthalmic compositions and methods of using the same: Ophthalmic compositions are provided that comprise or consist essentially of (a) ketotifen or a ketotifen salt, (b) a non-ionic tonicity agent, and (c) water. The concentration of ketotifen or the ketotifen salt is preferably from 0.01% to 0.05%. The non-ionic tonicity agent is preferably glycerol and the concentration of the... Agent:

20120004266 - Dopamine-beta-hydroxylase genetic polymorphism and migraine: The invention provides a method of determining whether or not an individual has a predisposition to migraine including the step of determining whether an isolated nucleic acid obtained from the individual comprises a nucleotide sequence corresponding to at least a fragment of a dopamine β-hydroxylase (DBH) gene promoter, wherein the... Agent: Griffith University

20120004267 - Apoptosis signal-regulating kinase inhibitors: e

20120004268 - Insecticidal compositions comprising cyclic carbonylamidines:

20120004269 - Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders: Provided are alkynyl phenyl derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.... Agent: Acucela Inc.

20120004270 - Selective androgen receptor modulators: This invention provides compounds as described herein or pharmaceutically acceptable salte thereof, pharmaceutical compositions comprising a compound as described herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor using the compounds or compositions described herein, methods of treating diseases beneficially treated... Agent: Radius Health, Inc.

20120004271 - Use of vaginally-administered insulin sensitizing agents: Use of vaginal insulin sensitising agents for the prevention and/or treatment of hyperandrogenism and/or polycystic ovary syndrome and/or related disorders.... Agent:

20120004272 - Biocidal composition of 2,6-dimethyl-m-dioxane-4-ol acetate and methods of use: Provided are compositions comprising 2,6-dimethyl-m-dioxane-4-ol acetate and a biocidal compound selected from the group consisting of: a biocidal oxazolidine; 1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane; and tris(hydroxymethyl)-nitromethane. The compositions are useful for controlling microorganisms in aqueous or water containing systems.... Agent:

20120004273 - Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders: o

20120004274 - Use of inhibitors of jun n-terminal kinases to treat glaucoma: Compositions and methods for lowering IOP and/or providing neuroprotection are disclosed. The compositions and methods are particularly directed to the use inhibitors of Jun N-terminal kinases (JNK) to lower IOP and/or provide neuroprotection.... Agent:

20120004275 - Sceletium extract and uses thereof: A composition including as an active ingredient an extract of a plant of the family Mesembryanthemaceae with mesembrenol and mesembrenone as the two major alkaloids present. The invention also relates to the use of the composition as a PDE4 inhibitor and as a serotonin-uptake inhibitor, preferably applied in formulations for... Agent: H.l. Hall & Sons Limited

20120004291 - Companion animal compositions including pyruvic acid and salts thereof and methods of use thereof: The invention encompasses pet food compositions and methods for the treatment and/or prevention of diseases or disorders in companion animals, for example, for the treatment or obesity, including administering a pet food composition including pyruvic acid or a salt thereof to a companion animal, or lipoic acid or salt thereof... Agent: Hill Pet Nutrition, Inc.

20120004292 - Composition for injection comprising an injection medicinal product and a gel: A composition of an injectable medicinal product and a gel, concentrating the medicinal product on-site to reinforce its action and/or reduce the toxicity of the medicinal product.... Agent:

20120004294 - Antitumor combination combining ave8062 and docetaxel: The invention relates to a sequential antitumor combination of AVE8062, or a salt thereof, and docetaxel, characterized in that AVE8062 is administered to a patient in a dose of 10 to 50 mg/m2, and then, on a different day of the week, preferably after a 24-hour interval, docetaxel is administered... Agent: Sanofi

20120004293 - Cancer cell targeting using nanoparticles: The present invention generally relates to polymers and macromolecules, in particular, to polymers useful in particles such as nanoparticles. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled... Agent:

20120004295 - Administration of 6'-ethyl lepimectin, 6'-methyl lepimectin or derivatives thereof for treating dermatological disorders in humans: 6′-ethyl lepimectin, 6′-methyl lepimectin or derivatives thereof are formulated into pharmaceutical compositions useful for the treatment of dermatological conditions in humans, in particular rosacea.... Agent: Galderma S.a.

20120004296 - Chroman derivatives, medicaments and use in therapy: Novel chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.... Agent: Marshall Edwards, Inc

20120004297 - Agent for alleviating vascular failure: An agent for alleviating, treating and preventing vascular failure and a vascular endothelial cell-protecting agent characterized by containing, as an effective ingredient, at least one active oxygen scavenger such as astaxanthin and tocotrienols; and a food, a drink and an animal feed having an effect of alleviating, treating and preventing... Agent: Fuji Chemical Industry Co., Ltd.

20120004298 - Ophthalmic devices containing chemokine antagonists: Ionic ophthalmic devices, methods of treating chemoattractant cytokine receptor 2 (CCR2) mediated inflammatory conditions, and methods of making such devices are disclosed herein.... Agent:

20120004299 - Azeotrope-like compositions of cis-1,1,1,4,4,4-hexafluoro-2-butene: and another material selected from the group consisting of water, fluoroketones, alcohols, hydrochlorofluoroolefins, and combinations of two or more thereof. These compositions may be used in a wide variety of applications such as, blowing agents, refrigerants, heating agents, power cycle agents, cleaning agents, aerosol propellants, sterilization agents, lubricants, flavor and... Agent: Honeywell International Inc.

20120004300 - Methods for treating bipolar disorder: The invention is directed to a method of treating bipolar disorder in a subject, comprising administering a therapeutically effective amount of a carbamate compound, or pharmaceutically acceptable salt or amide thereof.... Agent: Sk Holdings Co., Ltd.

20120004301 - Methods for treating restless legs syndrome: The invention is directed to a method of treating restless legs syndrome in a subject, comprising administering a therapeutically effective amount of a carbamate compound, or pharmaceutically acceptable salt or amide thereof.... Agent: Sk Holdings Co., Ltd.

20120004302 - Cosmetic use of n-substituted sulfonyloxybenzylamines and related compounds: Cosmetic compositions comprising N-substituted sulfonyloxybenzylamines and methods of using such compositions to impart anti-aging benefits to the skin are disclosed. The N-substituted sulfonyloxybenzylamines are believed to have modulatory activity against one or more biochemical pathways implicated in skin aging.... Agent: Avon Products, Inc.

20120004303 - Method of dispensing a teething gel with a metered dose applicator: A method of treating periodontal pain from teething that uses an applicator to dispense a medicament composition, wherein said applicator dispenses a metered dose of a therapeutic amount of said medicament composition.... Agent: Church & Dwight Co., Inc.

20120004304 - Bile salt adjuvant for animals for improving fat utilization efficiency in the bodies of animals, and animal feed comprising same: The present invention relates to a bile salt adjuvant for animals for improving fat utilization efficiency in the bodies of the animals, and to animal feed comprising same. More particularly, the present invention relates to a bile salt adjuvant for animals comprising sodium stearoyl-2-lactylate. The adjuvant is used in animal... Agent: Kimin Inc.

20120004305 - External preparation containing analgesic/anti-inflammatory agent: e

20120004306 - External preparation containing analgesic/anti-inflammatory agent: (C) a polyoxyalkylene alkyl ether and/or a polyoxyalkylene alkenyl ether. The external preparation of the present invention has improved the drug efficacy of a non-steroidal analgesic/anti-inflammatory agent, and can be effective at a low concentration. The external preparation of the present invention also has excellent appearance.... Agent: Kowa Co., Ltd.

20120004307 - Oral treatment of digital ischemic lesions: Provided are methods of orally treating ischemic diseases and conditions, such as digital ulcers, associated with or caused by the ischemic diseases.... Agent: United Therapeutics Corporation

20120004308 - Method for obtaining solid micro- or nanoparticles: The invention provides a novel method for obtaining solid micro- or nanoparticles with a homogeneous structure. A method is provided for obtaining solid micro- or nanoparticles with a homogeneous structure having a particle size of less than 10 μm where the processed solid compound has the natural, crystalline, amorphous, polymorphic... Agent: Consejo Superior De Investigaciones Cientificas

20120004309 - Hydroxamic acid derivatives, preparation and therapeutic uses thereof: Disclosed are amino alkyl/aryl hydroxamic acid compounds and pharmaceutical compositions containing such compounds. The disclosed compositions are useful as therapeutics for degenerative diseases in mammal.... Agent:

20120004310 - Non-peptide bdnf neurotrophin mimetics: Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule.... Agent:

20120004311 - Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic b-cell lymphoma/leukemia-2 (bcl-2): t

20120004312 - Synergistic combinations comprising a renin inhibitor for cardiovascular diseases:

20120004313 - Crystalline form vi of agomelatine, preparation method and application thereof: The invention provides a new crystalline form of agomelatine, preparation and use thereof. The X-ray powder diffraction diagram of the agomelatine crystalline form shows main peaks at the diffraction angles 2θ 11.13°, 11.82°, 17.49°, 18.29°, 19.48°, 19.72°, 20.50°, 21.76°, 22.54°, 22.97°, 24.56°, 25.36°, 27.16° and 31.93°. Said new crystalline form... Agent:

20120004314 - Antimicrobial composition: The invention relates to an antimicrobial composition comprising chlorhexidine and pentane-1,5-diol. Such a composition may be used to combat microorganisms.... Agent: Ambria Dermatology Ab

20120004315 - Selective estrogen receptor modulator: formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a... Agent:

20120004317 - Tapentadol for use in the treatment of irritable bowel syndrome: The invention relates to tapentadol for use in the treatment of Irritable Bowel Syndrome... Agent: Gruenenthal Gmbh

20120004316 - Treating impulse control disorders with catechol-o-methyl-transferase inhibitors: The invention provides methods for treating impulse control disorders in patients with catechol-o-methyl-transferase inhibitors. The invention also provides methods for treating patients with obsessive compulsive disorders and substance addictions with catechol-o-methyl-transferase inhibitors.... Agent:

20120004318 - Modified release formulations of memantine oral dosage forms: The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active... Agent: Forest Laboratories Holdings Ltd.

20120004319 - Process for producing carotenoid: The present invention provides a method for producing a carotenoid-containing composition, comprising the steps of: subjecting a culture of a carotenoid-producing microorganism to an extraction treatment using a water-soluble organic solvent; dispersing the resulting extract solution in water for micellization; heat stirring the resulting micellized solution in a solvent break... Agent:

20120004320 - Method for treating ocular demodex: The present invention relates to a method for treating a disorder chosen from ocular Demodex, Demodex-induced blepharitis, rosacea, acne, and meibomian gland dysfunction in a patient in need thereof, comprising administering to the patient a composition comprising a therapeutically effective amount of a substance chosen from at least one of... Agent: Tissuetech,inc.

20120004321 - Orally disintegrating tablet: It is an object to provide an orally disintegrating tablet produced by dry granulation and compression, having a hardness of 40 N or more, a disintegration time of 30 seconds or shorter, a friability of 0.1% or less, and an excellent feeling upon ingestion, that is capable of disintegrating with... Agent: Nipro Corporation

20120004322 - Piceatannol-containing composition and method of producing piceatannol-containing composition: Provided are a piceatannol-containing composition which is a composition originating in a natural material and containing piceatannol at a high concentration, and a method of producing the piceatannol-containing composition. A piceatannol-containing composition which contains 0.0001 to 99.9% by mass of piceatannol is obtained by extracting passion fruit seeds. The extraction... Agent: Morinaga & Co., Ltd.

20120004323 - Implant processing methods for thermally labile and other bioactive agents and implants prepared from same: Disclosed herein are processes for preparing implants that are particularly useful for thermally labile bioactive agents but can also generally be used with any bioactive agent. The disclosed processes avoid the use of heat during processing and therefore avoid heat induced degradation of the bioactive agent. Also disclosed are implants... Agent:

20120004324 - Process for preparing cyclic esters comprising unsaturated functional groups and polyesters prepared from same: Disclosed herein are process for preparing cyclic esters comprising unsaturated functional groups. Also disclosed are copolymers prepared from the cyclic esters. The copolymers can be used to form microparticles, polymer micelles, etc., which are useful in drug delivery applications.... Agent:

20120004325 - Insecticidal or acaricidal formulations with improved availability on plant surfaces: The invention relates to the use of compositions comprising at least one insecticide or acaricide, at least one nonionic and/or one ionic dispersant and an aqueous polymer dispersion for improving the availability of the insecticide or acaricide on plant surfaces.... Agent: Bayer Cropscience Ag

20120004326 - Isomers of bicyclo[2.2.1]hept-5-ene-2-carboxylic acid, ethyl ester and their use in perfume compositions: e

20120004328 - Lilian surrogate: Due to toxicological concerns, it may be desirable to replace the fragrance compound lilial with less problematic compounds without losing the creative power and quality regarding perfumes. The present invention addresses this need by using selected oxazolidines described herein.... Agent: Henkel Ag & Co. Kgaa

20120004327 - Water-insoluble reaction product of a polyamine and an oil-soluble high carbon polar modified polymer: The invention relates to a water-insoluble reaction product of an oil-soluble high carbon polar modified polymer and a polyamine.... Agent: L'oreal S.a.

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141218: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 3.80814 seconds

PATENT INFO